

Mef2c Controls Postnatal Callosal Axon Targeting by Regulating Sensitivity to Ephrin Repulsion

1 Sriram Sudarsanam^{1,2}, Luis Guzman-Clavel^{1,2}, Nyle Dar¹, Jakub Ziak¹, Naseer Shahid¹,
2 Xinyu O. Jin¹, and Alex L. Kolodkin^{1,3,4,*}

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

¹The Solomon H. Snyder Department of Neuroscience,
The Johns Hopkins Kavli Neuroscience Discovery Institute,
The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

²These authors contributed equally

³Senior author

⁴Lead contact

*Correspondence: kolodkin@jhmi.edu

20 ABSTRACT

21 Cortical connectivity is contingent on ordered emergence of neuron subtypes followed
22 by the formation of subtype-specific axon projections. Intracortical circuits, including
23 long-range callosal projections, are crucial for information processing, but mechanisms
24 of intracortical axon targeting are still unclear. We find that the transcription factor
25 Myocyte enhancer factor 2-c (*Mef2c*) directs the development of somatosensory cortical
26 (S1) layer 4 and 5 pyramidal neurons during embryogenesis. During early postnatal
27 development, *Mef2c* expression shifts to layer 2/3 callosal projection neurons (L2/3
28 CPNs), and we find a novel function for *Mef2c* in targeting homotopic contralateral
29 cortical regions by S1-L2/3 CPNs. We demonstrate, using functional manipulation of
30 EphA-EphrinA signaling in *Mef2c*-mutant CPNs, that *Mef2c* downregulates *EphA6* to
31 desensitize S1-L2/3 CPN axons to EphrinA5-repulsion at their contralateral targets. Our
32 work uncovers dual roles for *Mef2c* in cortical development: regulation of laminar
33 subtype specification during embryogenesis, and axon targeting in postnatal callosal
34 neurons.

35

36 HIGHLIGHTS

- 37 • *Mef2c* is required for the development of L4 and L5 neurons in the embryonic
38 neocortex
- 39 • Postnatally, *Mef2c* is enriched in L2/3 neurons and is required for axon targeting
- 40 • L2/3-specific *Mef2c* deletion leads to *EphA6* upregulation
- 41 • *Mef2c* deletion in L2/3 neurons sensitizes them to EfnA5 repulsion in the
42 contralateral cortex

43


44 KEYWORDS

45 Intracortical connectivity, corpus callosum, *Mef2c*, Ephrins, axon guidance, neocortex


46

Graphical abstract

Mef2c is necessary for L4 formation in embryonic postmitotic neurons



Mef2c Controls Postnatal Callosal Axon Targeting by Regulating Sensitivity to Ephrin Repulsion



47 INTRODUCTION

48 Ordered connectivity in the brain enables transformation of sensory stimuli into
49 meaningful perceptions, which in turn guides learning, memory and decision making. In
50 the mammalian brain, sensory integration and transformation primarily occur in the
51 cerebral cortex, mediated in part by long-range connections between cortical areas.
52 Layer 2/3 of the murine primary somatosensory cortex (S1) is home to a major
53 population of long-range intracortical projection neurons^{1,2}. These neurons elaborate
54 contralateral projections through the corpus callosum, the largest white-matter tract in
55 the mammalian brain, to mediate interhemispheric communication³. Corpus callosum
56 development proceeds in a stepwise fashion³⁻⁶, and recent advances have identified
57 callosal neuron-specific transcriptional regulators^{7,8,9,10} as well as extrinsic signals^{11,12},
58 which together regulate the initial channeling of axons into the white matter and promote
59 subsequent CNS midline crossing. Midline crossing is followed by topographically
60 organized target innervation, whereby callosal neurons innervate contralateral cortical
61 domains that match their region of origin in the ipsilateral cortex. Precise homotopic
62 targeting of callosal projections is crucial for information flow between cortical areas,
63 and deficits in callosal connectivity are associated with neurodevelopmental^{13,14,15} and
64 neuropsychiatric¹⁶ disorders. While there is some evidence for axon-axon interactions
65 directing homotopic callosal axon targeting¹⁷⁻¹⁹, the molecular determinants that operate
66 in callosal neurons and in their targets to promote appropriate axon targeting remain
67 elusive.

68 The Myocyte enhancer factor 2 (Mef2) family of four paralogous transcription factors
69 controls development and differentiation across different tissues²⁰. Of these, Mef2c
70 regulates several aspects of neuronal development, including neurogenesis and
71 differentiation²¹⁻²⁵, neuronal survival²⁶⁻²⁸, axon and dendrite elaboration^{23,24,29,30} and
72 synaptic development³¹⁻³⁷. Loss-of-function (LOF) mutations and deficiencies in *MEF2C*
73 are associated with conditions such as autism spectrum disorder, intellectual disability,
74 epilepsy and schizophrenia^{38,39}. *Mef2c* is broadly expressed in the cerebral cortex
75 during embryogenesis⁴⁰⁻⁴² and regulates the development of cortical laminar
76 organization²¹. Early broad expression of *Mef2c* in the embryonic cortex transitions
77 during postnatal development to laminar enrichment in superficial Layer 2/3 callosal

78 projection neurons (L2/3 CPNs)⁴¹, raising the possibility of important Mef2c functions in
79 callosal axon projection and targeting. Furthermore, the expression of several axon-
80 guidance genes is dysregulated following *Mef2c* deletion in the cortex^{34,37}, but to date
81 these alterations have not been functionally linked to specific defects in cortical
82 connectivity.

83 Among the dysregulated genes in the *Mef2c* mutant cortex are several Class-A Ephrin
84 receptors^{34,37}. Ephrins and their receptors were initially characterized as repulsive
85 regulators of axon guidance^{43,44} that underlie the formation of topographic maps⁴⁵, and
86 Ephrin-Eph signaling has also been implicated in many aspects of cortical development
87 ^{11,46–53}. Further, differential expression of the ligand *Ephrin A5 (EfnA5)* in the developing
88 cortex regulates area-specific innervation by axons from distinct thalamic nuclei, which
89 differ in their levels of *EphA* receptor expression ^{54–58}. Interestingly, L2/3 CPNs in S1
90 express low levels of *EphA* receptors^{59,60} and project to homotopic contralateral cortical
91 domains that exhibit high *EfnA5* expression. This raises the question of whether
92 differential expression of *EfnA5* in cortical areas is also functionally relevant for targeting
93 intracortical axons.

94 Here, we first investigate the function of embryonic *Mef2c* in cortical organization
95 following early pan-cortical deletion. We then explore postnatal roles for *Mef2c* in
96 callosal neuron axon outgrowth and targeting. To bypass non-autonomous effects of
97 disrupted cortical organization due to embryonic deletion of *Mef2c*, we employ *in utero*
98 electroporation-based strategies for robust post-mitotic L2/3 CPN-specific sparse
99 labeling and genetic manipulation. We assess candidate cell-surface molecules likely to
100 be regulated by Mef2c that influence callosal neuron axon targeting and identify a role
101 for EphrinA5-EphA signaling, downstream of *Mef2c*, for correct L2/3 CPN contralateral
102 S1 axon targeting. These results highlight the multifunctional roles served by Mef2c
103 during cortical development, and they reveal a novel role for Ephrin-Eph signaling,
104 downstream of Mef2c, in controlling homotopic target innervation during the
105 development of intracortical connectivity.

106 RESULTS

107 **Mef2c in post-mitotic neurons directs the development of cortical layers 4 and 5** 108 **during embryonic development**

109 An earlier study, employing *Mef2c* deletion starting in neural progenitors (*Nestin-Cre*;
110 *Mef2c^{FL/-}*), identified a role for *Mef2c* in embryonic cortical neuron differentiation and
111 laminar organization²¹. However, it remains unclear in which cell populations *Mef2c*
112 exerts this early embryonic function, and whether it is important for the development of
113 specific laminar subtypes of cortical neurons.

114 We first set out to identify the cell-types that express *Mef2c* in the developing murine
115 cortex. Hybridization Chain Reaction (HCR) *in situ* hybridization revealed that *Mef2c*
116 expression is confined to a thin band in the superficial portion of the cortical plate at
117 embryonic day 13.5 (E13.5, Figures 1A and 1A'). At E15.5, *Mef2c* is more broadly
118 expressed throughout the cortical plate (Figures 1B and 1B'). Of note, we did not detect
119 appreciable levels of *Mef2c* in the ventricular and sub-ventricular zones, indicating the
120 *Mef2c* expression is absent in the neural progenitors that populate these regions and
121 that it is restricted to post-mitotic neurons in the cortical plate.

122 In the light of this expression pattern, we asked whether cortical organization deficits are
123 recapitulated upon post-mitotic cortical neuron-specific *Mef2c* deletion. We chose the
124 *Nex-Cre (Neurod6-Cre)*⁶¹ transgenic line to recombine a conditional *Mef2c-flxed*
125 (*Mef2c^{FL}*) allele, in which the second coding exon is flanked by loxP sites⁶², in all post-
126 mitotic neurons of the dorsal telencephalon starting at E11.5.

127 We assessed laminar organization in the primary somatosensory cortex (S1) at
128 postnatal day 7 (P7) and observed a complete loss of Rorβ+(Rorb+) Layer 4 (L4)
129 neurons in *Nex-Cre; Mef2c^{FL/FL}* animals (Figures 1D, 1D' and 1H). This uncovers a
130 novel role for *Mef2c* in the development of cortical L4. The number of Ctip2+ (Bcl11b+)
131 Layer 5 (L5) neurons was also reduced in *Nex-Cre; Mef2c^{FL/FL}* animals (Figures 1F, 1F'
132 and 1J), as was cortical thickness (Figures 1C, 1C' and 1G), recapitulating observations
133 from the *Nestin-Cre; Mef2c^{FL/-}* condition²¹. The number and laminar position of L2/3
134 neurons was unchanged between control and mutants (Figures 1N, 1N' and 1R).
135 Differences in Layer 6 (Tle4+) were also not observed (data not shown).

136 *Rorβ*+ L4 neurons are the main recipients of thalamic input in primary sensory cortical
137 areas and are innervated by *Vglut2*+ thalamocortical axons, which segregate into barrel-
138 like structures in S1 (Figures S1P and S1Q). However, they fail to do so in *Nex-Cre*;
139 *Mef2c^{FL/FL}* animals that lack L4 (Figures S1P' and S1Q').

140 We next assessed cortical laminar organization in *Nex-Cre*; *Mef2c^{FL/FL}* brains at E16.5,
141 when L4 neurons have migrated into the cortex. The expression of *Rorβ*, a key
142 determinant of L4 neuron identity in sensory cortex^{63,64}, also increases in the cortical
143 plate (CP) at this stage⁶⁵. The CP *Rorβ* expression domain was greatly reduced in *Nex-*
144 *Cre*; *Mef2c^{FL/FL}* animals compared to *Nex-Cre*; *Mef2c^{FL/+}* littermates at E16.5 (Figures
145 S1A-S1B'). Specifically in the somatosensory region, *Rorβ* signal intensity was
146 significantly lower in the *Nex-Cre*; *Mef2c^{FL/FL}* mutants compared to heterozygous
147 littermates (Figures S1D vs 1D', and 1H). The number of *Brn2*+ (*Pou3f2*+) neurons
148 (Figures S1E, S1E' and S1J) and *Ctip2*+ neurons (Figures S1F, S1F' and S1K) in the
149 cortical plate was not significantly different between these two conditions. CP thickness
150 (Figures S1C, S1C' and S1G) and the total number of nuclei in the CP (DAPI+, Figure
151 S1I) were also unaltered. Reduced *Rorβ* expression coupled with normal expression of
152 other laminar subtype markers and cell numbers in the cortical plate supports *Mef2c*
153 specifically controlling acquisition of L4 neuron identity.

154 Since *Mef2c* has been reported to impact neuronal survival^{26,27}, we asked whether the
155 observed laminar subtype losses are due to elevated cell death. We observed similar
156 levels of cleaved-Caspase 3 (CC3) staining around the midline, a site of normal
157 apoptosis, in both controls and mutants (Figures S1M, S1M', S1O and S1O'), validating
158 our approach to detect cell death. However, we did not observe elevated CC3 in *Nex-*
159 *Cre*; *Mef2c^{FL/FL}* S1 cortex, compared to controls, at either E16.5 or P0 (Figures S1L,
160 S1L', S1N and S1N'). This result rules out increased apoptotic vulnerability of S1-L4
161 neurons in the absence of *Mef2c* and instead supports mis-specification to a different
162 identity that is not marked by commonly employed cortical laminar subtype markers.

163 Taken together, our results localize *Mef2c* function to post-mitotic neurons during
164 embryogenesis, and they reveal a new role for *Mef2c* in the development of specific
165 cortical neuron laminar subtypes, namely L4 and L5.

166 **Mef2c regulates L2/3 callosal projection neuron axon targeting during postnatal**
167 **development**

168 Next, we sought to determine whether, in addition to its role in laminar organization
169 during embryogenesis, Mef2c also contributes to postnatal cortical development. As a
170 first step, we documented *Mef2c* expression during the first postnatal week. We
171 observed strong *Mef2c* expression in superficial cortical layers (L2/3 and L4) of S1 at P0
172 (Figures 1K, 1K' and 1M left), which then shifts to a pattern of laminar-specific
173 enrichment in L2/3 at the end of the first postnatal week (Figures 1L, 1L' and 1M right).
174 This shift from earlier broad embryonic *Mef2c* cortical expression to robust L2/3-specific
175 expression during the first postnatal week has been previously documented⁴⁰, but its
176 functional relevance is unknown. Since this developmental period coincides with the
177 elaboration of axonal projections by L2/3 callosal projection neurons (L2/3 CPNs), we
178 hypothesized that *Mef2c* plays a role in axon outgrowth and/or guidance.

179 Pan-cortical deletion of *Mef2c* disrupts general organization of the cortex and is hence
180 unsuitable for assessing cell-autonomous contributions of *Mef2c* to L2/3 axon
181 projection. Therefore, we employed *in utero* electroporation (IUE) of a plasmid encoding
182 Cre recombinase (*pDcx-Cre*, restricted to post-mitotic neurons by the *Doublecortin*
183 promoter⁶⁶) into *Mef2c^{Floxed}* embryos at E15.5 to selectively target L2/3 CPNs (Figure
184 1D). A Cre-dependent fluorescent reporter plasmid (*pCAG-LSL-turboRFP*⁶⁷ or *pCAG-*
185 *LSL-EGFP*⁶⁸) was co-electroporated to visualize neuronal morphology. We observed
186 normal cortical laminar organization, including L4, upon E15.5 Cre-IUE into *Mef2c^{FL/FL}*
187 embryos (Figure S2A), validating the suitability of this approach for L2/3 CPN-
188 autonomous perturbation.

189 In control *Mef2c^{+/+}* and *Mef2c^{FL/+}* electroporated animals, S1-L2/3 CPNs send axon
190 projections across the corpus callosum to generate a prominent innervation column at
191 the boundary of contralateral S1 and secondary somatosensory cortex (S2) (Figures 1O
192 and 1O'). However, we observed a strong reduction in homotopic innervation of this
193 contralateral cortical domain upon Cre-IUE into S1-L2/3 CPNs in *Mef2c^{FL/FL}* animals
194 (Figures 1P and 1P'). Quantification of axonal fluorescence at the contralateral S1-S2
195 (cS1-S2) border, normalized to ipsilateral L2/3 electroporation intensity (see Methods),

196 was significantly lower in mutant brains compared to pooled *Mef2c*^{+/+} and *Mef2c*^{FL/+}
197 littermate controls (Figure 1Q). Control and mutant electroporated brains showed similar
198 levels of ipsilateral L2/3 cell labeling (Figures S2B, S2B' and S2C), indicating an
199 innervation deficit independent of electroporation efficiency. Intensity profiles of
200 innervation, along the Pia-to-WM axis, revealed a reduction in both deep and superficial
201 layers of the cS1-S2 domain in *Mef2c*^{FL/FL} mutants compared to controls (Figure 1R).
202 We also observed reduced innervation of domains more lateral to cS1-S2 in *Mef2c*^{FL/FL}
203 mutants compared to controls (Figures S2D-S2E'). Reduced cS1-S2 innervation was
204 not compensated by increased innervation of more medial domains within the barrel
205 field (Figures S2F-S2H).

206 S1-L2/3 neurons from *Mef2c*^{FL/FL} brains also displayed laminar specific innervation
207 deficits at ipsilateral long-range targets. Innervation was reduced in superficial, but not
208 deep, ipsilateral S2 layers (Figures S2K-S2L') and also in motor cortex (Figure S2M and
209 S2N). Additionally, we observed ectopic subcortical projections to the basolateral
210 amygdala in *Mef2c*^{FL/FL} brains (Figures S2K'' and S2L'').

211 These results reveal that *Mef2c* is crucial for targeting S1-L2/3 CPN axons to homotopic
212 domains in the contralateral cortex, and that it is also essential for guiding innervation of
213 superficial, but not deep, layers of distal ipsilateral targets.

214 **Dual labeling of WT and *Mef2c* conditional-mutant axons in the same brain** 215 **confirms cell autonomy of *Mef2c* function for callosal projection targeting**

216 Our IUE-based L2/3-specific *Mef2c* loss-of-function (LOF) paradigm strongly supports a
217 cell autonomous role for *Mef2c* in regulating homotopic targeting of callosal projections.
218 We further confirmed cell autonomy by comparing target innervation by WT and *Mef2c*
219 conditional-mutant callosal axons in the same brains by employing IUE-based dual-
220 labeling (Figure 2A). We co-electroporated a lower concentration of the *pTRE-Cre* with
221 higher levels of the *pCβA-Flex* construct⁶⁹, which expresses *tdTomato* in the absence
222 of Cre-recombination. In this scenario only a fraction of *pCβA-Flex* neurons also
223 express *pTRE-Cre*⁶⁷, and in those neurons *tdTomato* is excised and instead EGFP is
224 expressed. To ensure maximum recombination and robust GFP-labeling, we also co-
225 electroporated the Cre-dependent *pCAG-LSL-EGFP-ires-tTA*⁶⁷; tTA positively feeds

226 back to maximize *Cre* expression from the *TRE* promoter. As expected (Figure 2B), we
227 observed nearly exclusive labeling of electroporated L2/3 neurons with EGFP (*Cre*+) and
228 tdTomato (*Cre*-), and only a small fraction of double labeling (Figure S3A).

229 Both *Cre*+ and *Cre*- neurons innervated the cS1-S2 target in controls (Figures 2C, 2D
230 and 2E), however, only *Cre*-, but not *Cre*+, neurons innervated cS1-S2 in *Mef2c^{FL/FL}*
231 brains (Figures 2C', D' and E'). Quantification of the ratio of *Cre*+:*Cre*- innervation of
232 cS1-S2 revealed a reduction in mutants compared to controls (Figure 2F). *Cre*+:*Cre*-
233 intensity ratio at the corpus callosum midline was however not significantly different
234 between the two genotypes, indicating no deficit in midline crossing (Figures S3B-D). By
235 incorporating controls within the same brain, these results confirm the cell autonomy of
236 *Mef2c* contralateral S1-L2/3 CPN target innervation defects.

237 The *Mef2c^{Floxed}* allele produces a deletion of a large portion of the *Mef2c* DNA-binding
238 domain, but since the floxed exon is in-frame the rest of the protein is unaltered. We
239 therefore employed shRNA-based knockdown of *Mef2c*, by IUE in L2/3 neurons, as an
240 additional method for assessing *Mef2c* LOF. Contralateral innervation deficits were
241 recapitulated in this paradigm of *Mef2c* LOF (Figures 2G-2K, validation of knockdown in
242 Figures S3E-S3F"), further demonstrating that *Mef2c* function is crucial for callosal axon
243 target innervation.

244 ***Mef2c* specifically regulates target innervation, and not midline crossing, of** 245 **callosal projection neurons**

246 L2/3 CPN midline crossing appears unaffected in *Mef2c^{FL/FL}* brains at both P42 (Figures
247 S2O and S2P) and P15 (Figures S3B-D), suggesting a specific defect in the later
248 process of axon targeting. Ectopic projections to heterotopic cingulate cortical domains
249 in *Mef2c^{FL/FL}* brains (Figures S2I and S2J) further strengthen the case for a defect in
250 axon targeting rather than in outgrowth or midline-crossing. We sought to confirm the
251 specific function of *Mef2c* in callosal projection targeting, and not midline crossing, by
252 comparing the time-course of *Mef2c^{FL/+}* and *Mef2c^{FL/FL}* mutant S1-L2/3 callosal
253 projection development.

254 At P4 and P8, we observed normal midline crossing in both conditions (Figures 3A-3F),
255 confirming that *Mef2c* is dispensable for midline crossing. At P8, control S1-L2/3 CPN

256 axons broadly innervate the entire contralateral S1 cortical domain (Figures 3C and
257 3G). Mutant axons are confined to the white matter and do not enter the cortical plate
258 (Figures 3D, 3H and 3I), confirming that *Mef2c* is required for the initial target
259 innervation of S1-L2/3 CPN axons into the homotopic contralateral domain. During the
260 second postnatal week, control S1-L2/3 CPN axons in the more medial contralateral S1
261 are eliminated, while those at the cS1-S2 border persist and elaborate horizontal
262 branches in L2/3 and L5 to produce the columnar innervation characteristic of more
263 mature stages (Figures 3J and 3J'). *Mef2c^{FL/FL}* mutant axons remain confined to the
264 white matter (Figures 3K-L), ruling out the possibility that target innervation is recovered
265 after a delay.

266 These results show that *Mef2c* broadly regulates intracortical axon target innervation
267 without affecting axon outgrowth and midline crossing.

268 ***Mef2c* mutant L2/3 neurons exhibit aberrant connectivity at intercortical target** 269 **domains**

270 Is the loss of contralateral target innervation by *Mef2c* mutant S1-L2/3 CPN axons
271 accompanied by a concomitant decline in neuronal connectivity? To answer this
272 question, we co-electroporated a construct encoding the Cre-dependent, mCherry-
273 tagged, monosynaptic WGA (mWmC) anterograde tracer⁷⁰ along with *pDCX-Cre* and
274 *pCAG-LSL-EGFP* (cell label) constructs into control (*Mef2c^{+/+}* and *Mef2c^{FL/+}*) or
275 *Mef2c^{FL/FL}* E15.5 embryos. We then assessed connectivity as revealed by trans-
276 synaptic labeling at P42. In control brains, we detected several neurons with
277 perisomatic mWmC fluorescence in L5 and L2/3 of cS1-S2, coinciding with GFP+
278 axonal innervation (Figures 4C-4C' and 4E-4F'), strongly suggesting that they were
279 synaptically connected to electroporated S1-L2/3 CPNs in the ipsilateral cortex. In
280 *Mef2c^{FL/FL}* mutant brains, the number of connected mWmC+ neurons in cS1-S2 was
281 greatly reduced in both L2/3 and L5 (Figures 4D-4D', 4G-4H' and 4J), reflecting the
282 reduced axon innervation we observed in the absence of *Mef2c* (Figure 4I).

283 Local connectivity with partners in ipsilateral S1-L2/3 and L5 appeared grossly similar
284 between controls and mutants (Figures S4A-S4F'). At long range targets of S1-L2/3
285 neurons in the ipsilateral cortex, where innervation of superficial layers is reduced in

286 *Mef2c^{FL/FL}* IUE brains, we observed a corresponding decrease in the number of
287 mWmC+ connected neurons in superficial layers (Figures S4G-S4J). In addition, the
288 basolateral amygdala, which is ectopically targeted by *Mef2c^{FL/FL}* S1-L2/3 CPN axons,
289 was also densely packed with mWmC+ neurons, indicating that mis-targeted mutant
290 axons appear capable of forming synaptic connections.

291 Altogether, these results show *Mef2c* mutant L2/3 CPNs exhibit axon targeting deficits
292 reflected in a corresponding loss of connectivity with many contralateral S1 targets.

293 ***EphA6* expression is upregulated in *Mef2c*-mutant S1 L2/3 neurons**

294 How might *Mef2c* direct axonal targeting of a specific population of cortical neurons?

295 One possibility is that *Mef2c* is responsible for transcriptional control of L2/3 laminar
296 and/or S1-areal identity, and axonal mistargeting of *Mef2c*-mutant S1-L2/3 CPNs arises
297 due to these neurons adopting a different identity with distinct projection targets.

298 Alternatively, the expression of specific axon guidance genes that regulate callosal
299 projection targeting could be misregulated upon *Mef2c* LOF.

300 To test the first hypothesis, we evaluated the expression of L2/3 laminar identity
301 markers (Brn2, Figures S5A-S5C and Cux1, Figures S5D-S5F) and the S1 areal marker
302 Bhlhb5/Bhlhe22 (Figures S5G-S5I) in Cre-electroporated *Mef2c^{FL/FL}* neurons, compared
303 to *Mef2c^{FL/+}* controls. We did not find any differences in marker expression between the
304 two conditions, implying that post-mitotic *Mef2c* is dispensable for broad establishment
305 of L2/3 laminar and S1 areal identities. Nor did we observe elevated cell death in Cre-
306 electroporated *Mef2c^{FL/FL}* mutants (Figures S5J-S5L), ruling out projection deficits in the
307 mutant resulting from a loss of electroporated neurons.

308 Next, we consulted a published dataset comparing the bulk transcriptomes of pan-
309 cortical *Emx-Cre; Mef2c^{FL/FL}* mutant P21 cortices with *Mef2c^{FL/FL}* controls³⁴ to identify
310 candidate cell-surface molecules that might specifically affect callosal projection
311 targeting. The expression of several members of the *EphA* family of repulsive guidance
312 receptors, *EphA5*, *EphA6* and *EphA7*, whose cognate repulsive ligand *EfnA5* is
313 expressed in S1, are all upregulated in *Emx-Cre; Mef2c^{FL/FL}* mutants (Figure 5A).

314 Increased *EphA* receptor expression in *Mef2c*-mutant S1-L2/3 CPNs has the potential

315 to sensitize them to repulsion by the cognate ligand EfnA5 in contralateral S1^{54,58,71},
316 contributing to the observed innervation deficit in the absence of Mef2c.

317 To validate whether any of these receptors were upregulated specifically in L2/3 CPNs,
318 we performed HCR *in situ* hybridization on P7 brain sections from E15.5-Cre+GFP IUE
319 animals (Figure 5B). We observed that *EphA6* expression, but not *EphA7* expression, is
320 increased in *Mef2c*^{FL/FL} S1-L2/3 CPNs, compared to *Mef2c*^{FL/+} controls (Figures 5C-5E).

321 Together, these results support the hypothesis that *Mef2c* regulates callosal projection
322 targeting by controlling the expression of specific guidance molecules, rather than
323 broadly controlling areal and laminar identity acquisition during postnatal development.

324 ***EphA6* overexpression impairs contralateral target innervation by S1 L2/3** 325 **neurons**

326 As a first test of *EphA6-EfnA5* regulation of S1-L2/3 CPN axon contralateral targeting,
327 we assessed the effects of *EphA6* overexpression in WT S1 L2/3 CPNs on axon
328 projection. We first cloned C-terminal HA-tagged EphA6 ORF into a Flp recombinase-
329 dependent expression system developed for gene manipulation in cortical neurons^{72,73}.
330 We co-electroporated this construct with *pDcx-Cre*, Cre-dependent Flp (*TRE-DIO-*
331 *FlpO*)⁷⁴ and *pCAG-FSF-turboRFP-ires-tTA*, a construct which in addition to labeling
332 neurons drives Flp recombinase expression to promote maximum recombination of the
333 Flp dependent constructs, thereby ensuring high expression⁶⁸ (Figures 5G and S5M).

334 Fluorescence intensity in ipsilateral L2/3, a measure of electroporation efficiency, was
335 comparable between L2/3 CPNs that overexpressed *EphA6* and controls expressing
336 *GFP* (Figures 5H, 5I and 5K). Fluorescence intensity at cS1-S2, normalized to ipsilateral
337 L2/3 fluorescence, was significantly reduced in brains overexpressing *EphA6* compared
338 to *GFP* controls (Figures 5H', 5I' and 5J).

339 These results show that EphA6 overexpression in S1-L2/3 CPNs leads to reduced
340 contralateral target innervation, phenocopying *Mef2c* LOF and lending support to the
341 idea that *EphA6* downregulation by *Mef2c* is important for proper S1 L2/3 CPN axon
342 targeting.

343 **Loss of EphA6 function partially restores contralateral target innervation in *Mef2c***
344 **mutant L2/3 CPNs**

345 If *EphA6* downregulation by *Mef2c* is crucial for S1-L2/3 CPN contralateral target
346 innervation, *EphA6* LOF is expected to restore target innervation in *Mef2c* mutant S1
347 L2/3 CPNs. Eph-receptor tyrosine kinase signaling is dependent on cross-
348 autophosphorylation of intracellular domains in dimeric receptors assemblies⁷⁵. To
349 disrupt receptor function, we overexpressed a Flp-dependent *EphA6ΔIntra-Cellular*
350 *Domain (ICD)-GFP* construct in S1-L2/3 neurons by IUE, again employing our Cre + Flp
351 dependent cell labeling and overexpression strategy (Figure 6A). Receptor constructs
352 lacking the intracellular domains function as dominant-negatives when overexpressed
353 since they are incorporated in dimers with WT receptors, rendering them incapable of
354 signaling^{76,77} (Figure 6B). Overexpression of *EphA6ΔICD-GFP* in *Mef2c^{FL/+}* S1-L2/3
355 CPNs did not alter callosal projection or targeting as compared to expression of *GFP*
356 (Figures S6A-S6C), consistent with EphA6 function being dispensable for these
357 processes.

358 *Mef2c^{FL/FL}* S1-L2/3 CPNs expressing *EphA6ΔICD-GFP* displayed significantly higher
359 innervation of the cS1-S2 contralateral target compared to *Mef2c^{FL/FL}* S1 L2/3 CPNs that
360 expressed only GFP (Figures 6C-6E). We also observed lower ipsilateral L2/3
361 fluorescence intensity in *Mef2c^{FL/FL} + EphA6ΔICD-GFP* brains compared to *Mef2c^{FL/FL} +*
362 *GFP* brains (Figure 6F). This is likely due to a difference in IUE efficiency between the
363 two groups in this experiment. However, our quantification of cS1-S2 innervation
364 involves dividing cS1-S2 fluorescence intensity by ipsilateral L2/3 fluorescence intensity
365 to obtain a normalized innervation assessment, which is agnostic to differences in IUE
366 efficiency. Therefore, these results show that disruption of EphA6 receptor signaling in
367 *Mef2c* mutant L2/3 CPNs significantly restores contralateral target innervation.

368 In addition to disruption of EphA6 signaling using a dominant-negative EphA6 receptor,
369 we also employed shRNA-mediated knockdown of *EphA6* to assess its involvement in
370 S1-L2/3 CPN axon targeting downstream of *Mef2c* (Figure 6G). We co-electroporated
371 *EphA6*-targeting (*shEphA6*) or scrambled-control (*shScram*) shRNAs with an HA-tagged
372 *EphA6* construct and observed a loss of HA-immunofluorescence in *shEphA6* brains,

373 validating their efficiency (Figures S6G-S6H'). *shEphA6* expression in *Mef2c^{FL/+}* S1-L2/3
374 CPNs did not alter callosal projection or targeting as compared to expression of
375 *shScram* (Figures S6D-S6F), further demonstrating that *EphA6* is dispensable for
376 callosal axon development.

377 Unlike in the *EphA6ΔICD-GFP* experiment, we did not observe significant differences in
378 ipsilateral L2/3 fluorescence intensities in between *Mef2c^{FL/FL}* + *shEphA6* vs. *Mef2c^{FL/FL}*
379 + *shScram* (Figure 6K). As observed with *EphA6ΔICD-GFP* expression, *Mef2c^{FL/FL}* S1-
380 L2/3 CPNs that expressed *shEphA6* also displayed significantly stronger innervation of
381 the cS1-S2 contralateral target compared to *Mef2c^{FL/FL}* S1-L2/3 CPNs that expressed
382 *shScram* (Figures 6H-6J).

383 Taken together, these results show that disruption of *EphA6* function restores
384 contralateral target innervation by *Mef2c* mutant S1-L2/3 CPNs, supporting *Mef2c*
385 promotion of S1-L2/3 CPN target innervation through downregulation of *EphA6*
386 expression.

387 **Depletion of EphrinA5 in the contralateral S1 target domain restores innervation** 388 **by *Mef2c* mutant S1 L2/3 CPN axons**

389 *EphrinA5* (*EfnA5*), which encodes a repulsive ligand for *EphA6*, is broadly expressed in
390 S1 at the end of the first postnatal week, but not in more anterior/medial areal domains
391 such as motor and cingulate cortex (Figures 7A-7B'). This area specific *EfnA5*
392 expression coincides with the timing of L2/3 intracortical axon target innervation⁷⁸. We
393 hypothesized that *Mef2c* mutant S1-L2/3 CPN axons are sensitive to repulsion by
394 Ephrin ligands due to elevated *EphA6* expression and hence fail to innervate the *EfnA5*-
395 high S1 target domain, as depicted in Figure 7C. Deletion of *EphA6* in this context likely
396 restores contralateral targeting by suppressing sensitivity to EphrinA5 by *Mef2c* mutant
397 CPN axons. This model also predicts that depletion of *EfnA5* in the contralateral S1
398 target domain should have a similar effect.

399 To test this prediction, we conducted double-IUE experiments in *Mef2c^{FL/FL}* embryos.
400 First, at E12.5 we electroporated shRNA constructs targeting *EfnA5*, or scrambled
401 shRNA controls, into one brain hemisphere with the goal of depleting *EfnA5* across all
402 cortical layers. This was followed at E15.5 by IUE in these same embryos of constructs

403 expressing Cre and a cell-label in the contralateral hemisphere, deleting *Mef2c* in L2/3
404 CPNs and then observing axon development of these S1-L2/3 CPNs (Figure 7D). We
405 verified with HCR *in situ* hybridization that the E12.5 IUE of *shEfnA5* leads to depletion
406 of *EfnA5* in the electroporated cortex, including in deep layers (Figures S7D-S7G'). We
407 also confirmed that double-IUE appropriately targets deep layers of the E12,5
408 electroporated side, as well as labeling callosal neurons on the E15.5 electroporated
409 side (Figures 7E-7F'). Double-IUE in *Mef2c^{FL/+}* mice did not result in any differences in
410 *Mef2c^{FL/+}* S1 L2/3 CPN axon targeting to *shEfnA5*+ contralateral cortex, as compared to
411 *shScram*+ contralateral cortex (Figures S7A-S7C). This observation is consistent with
412 our model, in which control S1-L2/3 CPN axons are initially insensitive to *EfnA5*
413 repulsion and therefore loss of *EfnA5* at the contralateral target does not alter their
414 innervation pattern.

415 However, we observed that *shEfnA5* expression in contralateral S1 leads to increased
416 innervation of that same contralateral cortical domain by ipsilateral *Mef2c^{FL/FL}* S1 L2/3
417 CPNs, as compared to the innervation of *shScram*-electroporated S1 cortex by
418 *Mef2c^{FL/FL}* mutant ipsilateral S1-L2/3 CPNs (Figures 7G-7J). This observation
419 demonstrates that *Mef2c* mutant S1-L2/3 CPN axons are indeed sensitive to repulsion
420 by *EfnA5* at contralateral homotopic targets since the relief of repulsion by target-
421 specific *EfnA5* knockdown restores target innervation by *Mef2c* mutant CPN axons.

422 Together with our observations involving *EphA6* downregulation in *Mef2c^{FL/FL}* S1-L2/3
423 CPNs, our results show that downregulation of *EphA6* by *Mef2c* is necessary to prevent
424 L2/3 CPN axons from being repelled by *EfnA5* in the homotopic contralateral target
425 domain.

426 DISCUSSION

427 In this study, we report a novel role for *Mef2c* in mediating the targeting of callosal
428 projections from the somatosensory cortex (S1) to homotopic domains of the
429 contralateral cortex. Postnatal expression of *Mef2c* is enriched in callosal projection
430 neurons (CPNs), and using *in utero* electroporation-based strategies we have
431 developed that allow deletion of *Mef2c* specifically in S1-L2/3 CPNs combined with
432 robust labeling of axonal projections, we reveal strongly impaired projection to
433 contralateral homotopic targets following *Mef2c* LOF.

434 *MEF2C* LOF variants are strongly linked to neurodevelopmental and neuropsychiatric
435 disorders³⁸, and the expression of many axon guidance genes is dependent on
436 *Mef2c*^{34,37}. We establish here, to our knowledge, the first functional link between the
437 dysregulation of a specific axon guidance gene (*EphA6*) downstream of *Mef2c* deletion
438 and a corresponding deficit in interhemispheric connectivity by demonstrating that: (1)
439 overexpression of *EphA6* in S1-L2/3 CPNs reduces their contralateral innervation,
440 phenocopying *Mef2c* LOF; and (2) downregulation of *EphA6* function in *Mef2c*-mutant
441 S1-L2/3 CPNs significantly restores contralateral innervation. We also confirm that
442 *EphrinA5* (*EfnA5*), which encodes the repulsive ligand for *EphA6*, is highly expressed in
443 the somatosensory domain and we observe that downregulation of *EfnA5* in the target
444 cortex significantly restores contralateral innervation by *Mef2c* mutant S1-L2/3 CPNs.
445 Therefore, by downregulating *EphA6* levels *Mef2c* enables appropriate interpretation of
446 *EfnA5* areal expression to enable homotopic innervation by S1-L2/3 CPNs.

447 Our results further underscore the significance of repulsive guidance cues in shaping
448 topographic innervation maps⁷⁹. Area specific expression of the repulsive cue *EfnA5*,
449 coupled with complementary expression of *EphA* receptors, establishes distinct
450 domains that permit contralateral homotopic innervation while repelling projections from
451 heterotopic domains. Interestingly, patterned expression the *EfnA5* ligand also regulates
452 area-specific cortical innervation by thalamic axons^{56,58}. The establishment of 'go/no-go'
453 zones by a single cue, combined with differential responsiveness imparted by variation
454 in receptor levels between neuronal subtypes, illustrates how a limited number of cell-

455 surface molecules can orchestrate assembly of complex and highly specific circuit
456 wiring patterns.

457 In *Mef2c* conditional mutants, contralateral CPN targeting is prominently reduced as early
458 as P8, a time when wild type CPN axons first innervate their homotopic cortical domains.
459 The loss of contralateral innervation persists into adulthood and is accompanied by a loss
460 of connectivity in target regions. While other transcription factors like *Satb2* and
461 *NeuroD2/6* have been shown to regulate callosal projection elaboration, transcription
462 factors imparting specific effects on homotopic targeting after midline crossing remain to
463 be discovered. Therefore, transcriptional programs downstream of *Mef2c* offer a first
464 glimpse into the molecular logic that dictates patterns of homotopic targeting of callosal
465 projections.

466 The initial targeting deficit observed in *Mef2c*-mutant CPNs appears distinct from defects
467 arising due to impairment of developmental neuronal activity L2/3 CPNs^{9,80–83}. In these
468 cases, initial contralateral innervation is minimally altered at P8, and loss of innervation
469 is apparent only in the second postnatal week. These observations distinguish *Mef2c*-
470 dependent initial homotopic targeting of callosal axons from activity-dependent
471 refinement and selective axon process elaboration in the second postnatal week. On the
472 other hand, sensory-evoked activity-dependent strengthening of L4-to-L2/3 local,
473 ipsilateral, synaptic connectivity requires *Mef2c* in both post-synaptic L2/3 neurons and
474 pre-synaptic L4 neurons^{36,37}. Whether the functions of *Mef2c* in regulating long-range
475 CPN connectivity and in activity-dependent strengthening of local ipsilateral synapses
476 influence each other remains an open question.

477 Axon-axon interactions have been observed to affect topographic sorting of axons within
478 the corpus callosum^{17,19}, and matched cell-surface adhesion among axons of homotopic
479 ipsilateral and contralateral cortical regions has been suggested to influence axon
480 targeting¹⁸. Our results indicate that target-derived cues also regulate callosal projection
481 innervation, and they identify *EfnA5* as one of the first such examples. Indeed, the
482 observation that midline crossing and extension of axons within the white matter is
483 minimally affected in *Mef2c* mutants, and that only the innervation of the appropriate
484 region of the cortical plate is altered, support the idea that *EfnA5* exerts its effect at the

485 target rather than through axon-axon interactions along the tract. S1 L2/3 CPNs are
486 sensitive to EfnA5 repulsion only upon *Mef2c* deletion, and *Mef2c* LOF does not impact
487 the targeting of WT S1-L2/3 CPN axons, which express low levels of *EphA6*. What
488 function might ephrinA5 perform during the normal development of homotopic callosal
489 axon projections? EphA-receptor expression is high in more medial cortical domains,
490 including cingulate and retrosplenial cortices⁶⁰, and callosal axons from these regions
491 avoid contralateral motor and somatosensory domains. It is likely that high levels of *EfnA5*
492 in the somatosensory and motor cortical domains function to repel heterotopic projections
493 from these more medial regions.

494 The EphB2 receptor also functions as a target derived cue can regulate S1-L2/3 CPN
495 contralateral innervation^{53,84}. NMDA-dependent clustering of EphB2 on cortical neuron
496 dendrites restricts CPN axon targeting to the S1-S2 border and prevents excessive
497 innervation of the barrel field^{53,84}. This is thought to be mediated by callosal axon ephrin
498 B reverse signaling, but it remains unclear whether it involves initial targeting similar to
499 what is mediated by EfnA5, or later functions involving activity-dependent refinement of
500 contralateral projections in the second postnatal week.

501 Our manipulation of EfnA5-EphA6 signaling downstream of *Mef2c* significantly, but only
502 partially, restored contralateral CPN innervation, suggesting that additional mechanisms
503 promoting homotopic S1 cortex innervation operate downstream of *Mef2c*. Further
504 investigation of additional candidate cell-surface molecules whose expression is
505 regulated in *Mef2c* mutant cortical neurons may identify additional downstream
506 regulators, including those that directly promote callosal axon innervation of S1. It will
507 also be important to investigate intracellular signaling and cytoskeletal regulators that
508 regulate callosal axon projection, including candidates such as Kif2c, which has been
509 shown to promote axon branching downstream of *Mef2c*³⁰.

510 In addition to contralaterally projecting axons, S1-L2/3 harbors two additional major
511 populations of long-range intracortical projection neurons that project to ipsilateral M1 and
512 to ipsilateral S2, respectively^{1,85,86}. Deletion of *Mef2c* also caused target innervation
513 defects in these projections. However, unlike the complete loss of innervation of the
514 contralateral domain, *Mef2c* mutant L2/3 neurons show laminar-specific deficits in the

515 innervation of only the superficial, but not deep, layers of ipsilateral long-range targets.
516 Though our manipulations of EphrinA-EphA signaling downstream of *Mef2c* did not
517 rescue ipsilateral long-range targeting deficits, the remaining cell-surface molecules
518 whose expression is deregulated in the *Mef2c*-mutant cortex^{34,37} offer an opportunity to
519 discover novel regulators of long-range intracortical axon targeting.

520 *Mef2c*-mutant S1 L2/3 CPNs also displayed ectopic subcortical innervation, including
521 robust projections to the ipsilateral basolateral amygdala (BLA). Given the crucial role of
522 the amygdala in social and emotional processing⁸⁷, and the association of
523 neurodevelopmental disorders with amygdala function defects⁸⁸, it will be interesting to
524 investigate the behavioral consequences of S1 CPN ectopic projections to the BLA.

525 In addition to defining a novel role for *Mef2c* in postnatal callosal projection targeting, we
526 shed new light on the role of *Mef2c* in cortical neuron differentiation during
527 embryogenesis. We localized the embryonic function of *Mef2c* to postnatal cortical
528 neurons, not neural progenitors, and we also observe a novel requirement for post-mitotic
529 *Mef2c* in the development of *Rorβ*+ cortical L4 neurons. Reduced *Rorβ* mRNA expression
530 in the embryonic cortex of *Nex-Cre; Mef2c^{FL/FL}* mutants foreshadows the absence of any
531 *Rorβ*+ neurons in the S1 cortex at postnatal stages. We did not detect elevated cell death
532 upon pan-cortical deletion of *Mef2c* at embryonic or early postnatal stages, suggesting
533 that L4 neurons, rather than being lost to cell death, are mis-specified into a different class
534 of neuron lacking expression of many cortical laminar subtype markers.

535 *Rorβ*+ L4 neurons are a characteristic feature of primary sensory cortical areal
536 organization, distinguishing S1 from more frontal/motor areas⁸⁹. Pilot assessments of
537 cortical areal marker expression in *Nex-Cre; Mef2c^{FL/FL}* brains revealed that, concomitant
538 with the *Rorβ*+ L4 neuron loss, there is a downregulation of S1-areal markers and
539 upregulation of frontal/motor markers in *Nex-Cre; Mef2c^{FL/FL}* mutants (data not shown).
540 Future investigations will shed light on how laminar-subtype specification and areal
541 identity acquisition are coordinated by *Mef2c* during post-mitotic cortical neuron
542 development.

543 Taken together, our work highlights the multifunctional roles served by *Mef2c* during
544 cortical development: in the embryonic development of cortical laminar organization and

545 in postnatal homotopic targeting of callosal projections. Importantly, we identify a novel
546 role for EfnA5-EphA signaling in orchestrating callosal projection targeting downstream
547 of Mef2c. These results offer a first glimpse into the molecular logic underlying homotopic
548 organization of callosal projections. *MEF2C* loss-of-function is strongly associated with
549 neurodevelopmental and neuropsychiatric disorders^{38,39}, as is aberrant intracortical
550 connectivity that includes disrupted callosal projection homotopy^{14–16}. Our
551 characterization of Mef2c as a regulator of intracortical projection targeting suggests that
552 the molecular programs regulated by MEF2C will provide crucial insights into the etiology
553 of aberrant interhemispheric connectivity in neurodevelopmental and neuropsychiatric
554 disorders, with the potential for offering therapeutic intervention targets. Moreover, since
555 *MEF2C* is highly expressed in other brain regions during development, including in
556 regions of the cerebellum, hippocampus and lateral amygdala^{38,60}, this work may help
557 address roles played by Mef2c more widely in the regulation of axon projection targeting
558 across multiple brain regions.

559 **Limitations of this study**

560 Though we show that downregulation of *EphA* receptor expression by Mef2c is necessary
561 for homotopic innervation by S1-L2/3 CPNs, it remains to be determined whether *EphA6*
562 transcription is directly repressed by Mef2c or if a different Mef2c target downregulates
563 *EphA6* expression. Mef2c can function as both a transcriptional repressor and activator;
564 repressor function is crucial in establishing excitatory/inhibitory synaptic balance during
565 cortical development³⁴, and activator function modulates activity-dependent
566 strengthening of L4->L2/3 connectivity³⁷. Functional assessment of potential Mef2c-
567 binding sequences in close to the *EphA6* TSS will address whether it is a direct target of
568 Mef2c.

569

570 **MATERIALS AND METHODS**

571 **EXPERIMENTAL MODEL DETAILS**

572 *Mice*

573 Experiments were carried out in strict accordance with the recommendations in the
574 *Guide for the Care and Use of Laboratory Animals* of the National Institutes of Health.
575 The animal protocol was approved by the Animal Care and Use Committee of The
576 Johns Hopkins University School of Medicine (Protocol #M023M68). Mice of both sexes
577 were used in all experiments. Noon of the day after the plug was designated as E0.5,
578 and the date of birth as P0. Mice used in all experiments were group housed and
579 maintained in a 14/10-hour (h) light/dark (LD) cycle and had access to food and water
580 *ad libitum*.

581 *Mef2c*-floxed mice in the C57BL6/J background (*Mef2c^{tm1Jjs}/J*, Jax Strain #025556),
582 kindly shared by John Schwarz⁶², were crossed to WT CD1 mice (Charles River
583 Laboratory) and maintained on a mixed background as heterozygotes and
584 homozygotes. *Nex-Cre (Neurod6-Cre)^{tg/tg}* mice in the C57BL6/J background, a gift from
585 Klaus-Armin Nave⁶¹, were crossed to mixed-background *Mef2c^{F1/F1}* mice to generate
586 *Mef2c^{F1/+}; Nex-Cre^{Tg/+}* stock. Timed pregnant CD1 females were obtained from Charles
587 River Laboratory (Strain code 022) for WT IUE experiments.

588 **METHODS**

589 *Oligonucleotide Sequences*

shRNA Target sequences ⁹⁰ :
<i>shScrambled_1</i> : TAGATAAGCATTATAATTCCTA
<i>shScrambled_2</i> : TTAATCAGAGACTTCAGGCGG
<i>shScrambled_3</i> : ATAAATTCCTCCCTGACTTCGC
<i>shMef2c.1305</i> : TAAAGTAGGAGTTGCTACGGAA

<i>shMef2c.1868:</i> TTTTACAAAACAGAGTACCTGA
<i>shEphA6.3044:</i> TTGTTGTATAAGCTGCTTCTGG
<i>shEphA6.1288:</i> TTTAGGAGTATCTCGCTCCTCA
<i>shEphA6.2648:</i> TTTTAGTGACAACACCTTCTAG
<i>shEfnA5.633:</i> TTGAGCTTTAGACAGGACCTTC
<i>shEfnA5.626:</i> TTAGACAGGACCTTCTTCCGTT
Genotyping Primers:
<i>Mef2c-loxP-F:</i> TTCAGGTGACCTCATTGAACC
<i>Mef2c-loxP-R:</i> GGAGCCATTGCTCATAAGAAAG

590

591

592 *Plasmids*

593 *pDCX-Cre-ires-mCherry*, modified from *pDCX-Cre-ires-GFP*⁶⁶, was kind gift from
594 Soraia Barao and Ulrich Mueller, and *pC β A-Flex*⁶⁹ was a gift from Ulrich Mueller. *pTRE-*
595 *Cre* (Addgene #69136) and *pCAG-Lox-Stop-Lox-turboRFP-ires-tTA-WPRE* (*pCAG-*
596 *LSL-tRFP-ires-tTA*, Addgene #69138)⁶⁷, as well as *pCAG-Lox-Stop-Lox-EGFP-WPRE* (*pCAG-*
597 *LSL-GFP-ires-tTA*, Addgene #85006) and *pCAG-FRT-Stop-FRT-turboRFP-ires-*
598 *tTA-WPRE* (*pCAG-FSF-tRFP-ires-tTA*, Addgene #85038) were gifts from Takuji
599 Iwasato. *pCAFNF-EGFP* (Addgene #13722)⁹¹ was a gift from Constance Cepko, *pTRE-*
600 *DIO-FlpO* (Addgene #118027)⁷⁴ from Minmin Luo, *pCAG-Flex-mWGA-mCherry-WPRE*
601 (*pCAG-Flex-mWmC*)⁷⁰ from Xin Duan, and *pCAG-FlpO* (Addgene #125576)⁹² from
602 Takeshi Imai.

603 To generate the *pCAG-FSF-EphA6-HA* overexpression construct, the C-terminal HA-
604 tagged *EphA6* cDNA ORF (Sino Biological MG50630-CY) was excised as a KpnI-NotI
605 fragment and cloned in to the corresponding sites of *pCAFNF-EGFP*, replacing the GFP
606 cassette.

607 To generate the *pCAG-FSF-EphA6 Δ IntraCellularDomain(ICD)-GFP*, a PCR fragment
608 including the N-terminal extracellular region and transmembrane domain and only the
609 first 4 amino acids of the intracellular domain was amplified from the full-length *EphA6*
610 cDNA ORF (Sino Biological MG50630-CY), fused with an in-frame *EGFP* sequence in
611 an intermediate cloning vector (Randal Hand and Alex Kolodkin, unpublished), and then
612 cloned into the XhoI-NotI sites of *pCAG-FSF-ires-GFP*⁷², replacing the *ires-GFP*
613 cassette.

614 To generate the *pCAG-FSF-GFP-shmiRE* cloning vector, the *miR30* backbone was
615 excised as an NotI-MscI fragment from *pPRIME-dsRed-shScram*⁹³ and cloned into the
616 corresponding sites of *pCAG-FSF-GFP*⁷², downstream of the GFP cassette. The *FSF*
617 cassette was excised to generate the Flp-independent *pCAG-GFP-shmiRE* vector.
618 *shRNA* target sequences for the genes of choice were selected from a previous study⁹⁰,
619 and 97-bp oligomeric DNA corresponding to *miR30E-shRNA* sequence, as specified in
620 Fellman *et al* 2013⁹⁰, were synthesized. Oligomers were PCR amplified with *XhoI-site-*
621 containing forward and *EcoRI-site-*containing reverse primers to generate inserts that

622 were then cloned into the XhoI-EcoRI sites of the appropriate vector (*pCAG-FSF-GFP-*
623 *shmiRE* for *shEphA6*, and *pCAG-GFP-shmirE* for *shMef2c* and *shEfnA5*). The target
624 sequences of all *shRNAs* used in this study are listed in the Oligonucleotide Sequences
625 table above.

626 All plasmids generated in this study were validated by sequencing, and the NucleoBond
627 Xtra Midi EF kit (Takara Bio 740422.50) was used for endotoxin-free preparation of all
628 plasmids used for IUE.

629 *In Utero Electroporation*

630 *In utero* electroporation to target S1 L2/3 or deep layer neuronal progenitors were
631 performed, on E15.5 or E12.5 timed-pregnant mice, as previously described^{72,73,78}.
632 Briefly, time-pregnant mice were anesthetized with 2% isoflurane and placed on a
633 heating pad. The abdomen was shaved and cleaned, 100uL of the local anesthetic
634 Bupivacaine-hydrochloride (2.5 mg/mL; Sigma B5274-5G) was applied, and a 1.5-2 cm
635 laparotomy was made. Pups were extracted and rinsed with sterile warmed PBS. Pups
636 were injected in one lateral ventricle using glass needles pulled on a vertical pipette
637 puller (Narishige PC-10), and electroporated with three 40 V pulses (E15.5) or five 36 V
638 pulses (E12.5) of 50 ms duration delivered at 1 Hz, administered using a BTX ECM 830
639 square pulse electroporator (Harvard Apparatus) via 5mm gold-plated paddle electrodes
640 (BTX 450170, Fischer Scientific) at E15.5 or CUY650P3 3-mm round tweezer
641 electrodes (NepaGene) at E12.5. DNA constructs were mixed in PBS with Fast Green
642 FCF dye (Sigma F7258-25G) to visualize injections. 0.75 μ L of Buprenorphine (1
643 mg/mL; ZooPharm LLC) was administered for post-operative pain control.

644

645 The following plasmid combinations were used in this study:

646 For S1 L2/3 CPN-specific *Mef2c* conditional knockout, *Mef2c^{Fl/+}* E15.5 timed pregnant
647 females (crossed with *Mef2c^{Fl/+}* males) were injected with *pDcx-Cre-ires-mCherry* (0.6
648 μ g/ μ L) and either *pCAG-LSL-tRFP-ires-tTA* (1.0 μ g/ μ L) or *pCAG-LSL-GFP-ires-tTA* (1.5
649 μ g/ μ L). *mCherry* is no longer expressed from the *DCX*-promoter at all postnatal stages
650 analyzed in this study, and only the other, Cre-dependent, fluorophore is detected.

651 For dual labeling, *Mef2c*^{FL/+} E15.5 timed pregnant females (crossed with *Mef2c*^{FL/+}
652 males) were injected with *pTRE-Cre* (0.125 µg/µL), *pβA-Flex* (1.5 µg/µL) and *pCAG-*
653 *LSL-GFP-ires-tTA* (1.5 µg/µL).

654 For S1 L2/3 CPN-specific *Mef2c* knockdown in WT CD1 E15.5 timed pregnant females,
655 half the embryos were injected with *pCAG-mCherry* (1.5 µg/µL) and a pool of 2 *pCAG-*
656 *GFP-shMef2c* plasmids, each expressing a different *Mef2c* targeting *shRNA* (0.75 µg/µL
657 each); the rest of the embryos were injected in the opposite hemisphere with *pCAG-*
658 *mCherry* (1.5 µg/µL) and a pool of 2 *pCAG-GFP-shScram* plasmids, each expressing a
659 different scrambled-control *shRNA* (0.75 µg/µL each).

660 For WGA-anterograde tracing, *Mef2c*^{FL/+} E15.5 timed pregnant females (crossed with
661 *Mef2c*^{FL/+} males) were injected with *pDcx-Cre-ires-mCherry* (0.6 µg/µL), *pCAG-Flex-*
662 *mWmC* (1.5 µg/µL) and *pCAG-LSL-GFP-ires-tTA* (1.5 µg/µL).

663 For *Epha6* overexpression, *pDcx-Cre-ires-mCherry* (0.6 µg/µL) *pTRE-DIO-FlpO* (0.6
664 µg/µL) and *pCAG-FSF-tRFP-ires-tTA* (1 µg/µL) were mixed with either *pCAG-FSF-*
665 *Epha6-HA* (1.5 µg/µL) or *pCAFNF-GFP* (1.5 µg/µL). In WT CD1 E15.5 timed pregnant
666 females, half the embryos were injected, in the same hemisphere, with *Epha6-HA* mix,
667 while the other half were injected, in the other hemisphere, with *GFP* mix.

668 For *Epha6ΔICD* expression, *pDcx-Cre-ires-mCherry* (0.6 µg/µL) *pTRE-DIO-FlpO* (0.6
669 µg/µL) and *pCAG-FSF-tRFP-ires-tTA* (1 µg/µL) were mixed with either *pCAG-FSF-*
670 *Epha6ΔICD-GFP* (1.0 µg/µL) or *pCAFNF-GFP* (1.0 µg/µL). In *Mef2c*^{FL/+} E15.5 timed
671 pregnant females (crossed with *Mef2c*^{FL/FL} males), half the embryos were injected, in
672 the same hemisphere, with the mix containing *Epha6ΔICD-GFP*, while the other half
673 were injected in the other hemisphere with control mix that contained *pCAFNF-GFP*
674 instead.

675 For *Epha6* knockdown, *pDcx-Cre-ires-mCherry* (0.6 µg/µL) *pTRE-DIO-FlpO* (0.6 µg/µL)
676 and *pCAG-FSF-tRFP-ires-tTA* (1 µg/µL) were mixed with either a pool of three *pCAG-*
677 *FSF-GFP-shEpha6* plasmids, each expressing a different *Epha6* targeting *shRNA* (0.6
678 µg/µL each), or with a pool of three *pCAG-FSF-GFP-shScram* plasmids, each
679 expressing a different scrambled-control *shRNA* (0.6 µg/µL each). In *Mef2c*^{FL/+} E15.5
680 timed pregnant females (crossed with *Mef2c*^{FL/FL} males), half the embryos were injected

681 in the same hemisphere with *shEphA6* mix, while the other half were injected in the
682 other hemisphere with *shScram* mix.

683 For shRNA validation, either the *pCAG-FSF-GFP-shEphA6* pool (3 x 0.6 µg/µL) or the
684 *pCAG-FSF-GFP-shScram* pool (3 x 0.6 µg/µL) was mixed with *pCAG-FlpO* (0.6 µg/µL)
685 and *pCAG-FSF-EphA6-HA* (1.5 µg/µL). In WT CD1 E15.5 timed pregnant females, half
686 the embryos were injected in the same hemisphere with *shEphA6* mix, while the other
687 half were injected in the other hemisphere with *shScram* mix.

688 For *EfnA5* knockdown by double IUE, all embryos in *Mef2c^{FL/FL}* E15.5 timed pregnant
689 females (crossed with *Mef2c^{FL/+}* males) were first injected in the same hemisphere with
690 a pool of two *pCAG-GFP-shEfnA5* plasmids (0.75 µg/µL each) for the Contra-*shEfnA5*
691 condition, or, with a pool of two *pCAG-GFP-shScram* plasmids (0.75 µg/µL each) for the
692 Contra-*shScram* condition. Three days later, at E15.5, the same timed pregnant
693 mothers were subjected to a second IUE. At this stage all embryos were injected in the
694 hemisphere opposite to E12.5 injection with a mix of *pDcx-Cre-ires-mCherry* (0.6 µg/µL)
695 *pTRE-DIO-FlpO* (0.6 µg/µL) and *pCAG-FSF-tRFP-ires-tTA* (1 µg/µL). The same double
696 IUE experiments were also performed with *Mef2c^{FL/+}* timed pregnant females crossed
697 with *Mef2c^{+/+}* males.

698 To validate efficiency of *EfnA5* knockdown, CD1 WT E12.5 timed pregnant females
699 were injected in a single hemisphere with the pool of two *pCAG-GFP-shEfnA5* plasmids
700 (0.75 µg/µL each).

701

702 *Immunohistochemistry in thick brain sections to visualize axon projections*

703

704 Mice younger than P7 were deeply anesthetized on ice, and mice P7 or older were
705 deeply anesthetized with CO₂. They were then transcardially perfused with ice-cold
706 phosphate-buffered saline (PBS), followed by 4% paraformaldehyde (Electron
707 Microscopy Sciences #15711) in PHEM buffer (27 mM PIPES (Amresco; 0169-250G),
708 25 mM HEPES (Sigma; H3375-500G), 5 mM EGTA (Amresco; 0732-1006), 0.47 mM
709 MgCl₂ (Sigma; M8266-100G), pH 6.9) with 10% sucrose and 0.1% Triton X-100 (4%
710 PFA/PHEM). Brains were dissected and evaluated for IUE efficiency under a
711 fluorescence dissection microscope. Brains with very low signal intensity or very high

712 IUE signals outside the S1 region were discarded at this stage. Brains with good, S1-
713 specific IUE signal were post-fixed in 4% PFA/PHEM overnight (O/N) at 4°C. Fixed
714 brains were washed in PBS 3 times, 1 hour each, and stored in sealed containers at
715 4°C for until sectioning. 250-µm coronal sections were prepared using a vibratome
716 (Leica VT1000s). Sections were then washed 3x in PBS, and treated with
717 permeabilization solution (0.1% Triton X-100 and 3% Bovine Serum Albumin) in PBS for
718 1 hour at RT, and incubated overnight at 4°C in blocking solution (permeabilization
719 solution + 5% Normal Goat Serum (NGS, Jackson ImmunoResearch 005-000-121) with
720 primary antibodies. The following primary antibodies were used at the indicated
721 concentration: rabbit anti-tagRFP (Thermo Fisher MA5-32668), 1:1000; chicken anti-
722 GFP (Aves GFP-1020), 1:1000; rabbit anti-dsRed (Takara Bio 632496); 1:1000; rat anti-
723 HA (Sigma 11867423001), 1:500; rabbit anti-Mef2c (Cell Signaling 5030S), 1:1000.
724 Sections were then washed 3x in PBS and incubated overnight at 4°C in PBS + 0.1%
725 Triton X-100 with secondary antibodies and DAPI (Fisher Scientific D1306). Finally,
726 sections were washed 3x in PBS, mounted with Aqua Polymount (Polyscience Inc.
727 18606-20) on Superfrost Plus™ (Fisher Scientific 12-55-15) slides, and then stored at
728 4°C until imaging. The following cross-adsorbed secondary antibodies were used at a
729 1:1000 dilution: goat anti-rabbit Alexa Fluor 555 (Invitrogen A21429); goat anti-chicken
730 Alexa Fluor 488 (Invitrogen A32931); goat anti-rabbit Alexa Fluor 647 (Invitrogen
731 A21245); and goat anti-rat Alexa Fluor 488 (Invitrogen A48262).

732

733 *Immunohistochemistry and In Situ Hybridization Chain Reaction (HCR) in Thin Coronal* 734 *Brain Sections*

735

736 P7-8 mice E16.5 timed pregnant females were deeply anesthetized with CO₂, and P0
737 mice with ice. They were then transcardially perfused with ice-cold, RNase-free
738 phosphate-buffered saline (PBS), followed by RNase-free 4% PFA in PBS. Brains were
739 then isolated from embryos and pups, and post-fixed overnight in RNase-free 4% PFA-
740 PBS overnight at 4°C. Brains were then washed in PBS 3 times, 1 hour each, and
741 cryoprotected overnight in RNase-free PBS + 30% Sucrose at 4°C. The next day, tissue
742 was frozen over dry ice in NEG-50 (Thermo Fisher 22-046-511) blocks. Fixed-frozen

743 brains were cryosectioned at thickness of 16 μ m on a Leica CM3050 cryostat. Sections
744 spanning the entire somatosensory cortex were collected on Superfrost Plus™ (Fisher
745 Scientific 12-55-15) slides. Fixed-frozen tissue blocks and cryosection slides were
746 stored at -80°C until use.

747
748 HCR probe hybridization and amplification were carried out according to manufacturer's
749 protocol (molecularinstruments.com) for fixed-frozen cryosections. Hybridization was
750 performed overnight with HCR probes designed and synthesized by Molecular
751 Instruments against the following *Mus musculus* mRNA sequences: *Mef2c* (compatible
752 with HCR-hairpins B2), *Ror β* (B1), *Pax6* (B1), *EphA6* (B5), *EphA7*(B4) and *EfnA5* (B2).
753 20 pairs of probes, each at a concentration of 4nM, were used per mRNA. This was
754 followed by overnight room-temperature amplification with HCR-hairpins coupled to
755 AlexaFluor 546 or 647, compatible with the appropriate initiators, at a concentration of
756 60nM. Slides were then washed with 5X SSCTw (Saline-Sodium Citrate Buffer + 0.1%
757 Tween-20) before proceeding to immunohistochemistry (IHC). If only HCR was
758 required, slides were counterstained with DAPI and mounted with Aquapolymount after
759 5X SSCTw washes.

760
761 For IHC, sections were first blocked with 10% NGS in PBS+0.1%Triton for 1 hour at RT
762 followed by overnight 4°C staining with primary antibodies in the same blocking solution.
763 The following primary antibodies were used on thin sections: Chicken anti-GFP (Aves
764 GFP-1020), 1:500; Rabbit anti-Brn2 (Cell Signaling 12137S), 1:1000; Mouse anti-Ror β
765 (Perseus Proteomics PP-N7927-00), 1:250; Rat anti-Ctip2 (Abcam ab18465), 1:1000;
766 Rabbit anti-Cux1 (Proteintech 11733-1-AP), 1:500; Rabbit anti-Cux2 (Proteintech
767 24902-1-AP), 1:500; Rabbit anti-Cleaved Caspase 3 (Cell Signaling 9661), 1:500;
768 Rabbit anti-Bhlhb5 (Abcam ab204791), 1:1000 and Guinea Pig anti-Vglut2 (Sigma
769 Aldric ab2251-I), 1:500. Sections were then washed 3x in PBS at RT and incubated for
770 2hr at RT in PBS + 0.1% Triton X-100 with secondary antibodies and DAPI (Fisher
771 Scientific D1306). Finally, sections were washed 3x in PBS and mounted with
772 Aquapolymount (Polyscience Inc. 18606-20) and stored at 4°C until imaging. The
773 following cross-adsorbed secondary antibodies were used at a 1:500 dilution: goat anti-

774 rabbit Alexa Fluor 647 (Invitrogen A21245), goat anti-rabbit Alexa Fluor 488 (Invitrogen
775 A11034), goat anti-rabbit Alexa Fluor 555 (Invitrogen A21429), goat anti-chicken Alexa
776 Fluor 488 (Invitrogen A32931), goat anti-rat Alexa Fluor 488 (Invitrogen A48262), goat
777 anti-rat Alexa Fluor 647 (Invitrogen A21247) and goat anti-guinea pig Alex Fluor 647
778 (Invitrogen A21450).

779

780 *Confocal Imaging of Brain Sections*

781 All imaging was performed on a Zeiss LSM700 confocal microscope controlled by Zen
782 2012 SP5 software (Zeiss).

783

784 Tiled images of entire thick coronal sections were acquired with a 10X objective (NA
785 0.3) at 1.25 μm x 1.25 μm pixel size in xy and z-intervals of 20 μm , spanning the entire
786 tissue depth. Two separate images were acquired of each section, one at high laser
787 intensity and gain to visualize axon projections, and a second at lower laser intensity
788 and gain to obtain images where ipsilateral L2/3 cell body fluorescence was not
789 saturated. Laser power and gain settings for the low and high intensity conditions were
790 kept constant for all brains that were quantified and compared as part of any single
791 experiment.

792

793 Tiled images of the cS1-S2 border region in EGFP-tdTomato dual-labeled brains were
794 obtained with a 20X (NA 0.8) objective at 0.31 μm x 0.31 μm pixel size in xy and z-
795 interval of 1.5 μm , spanning the entire tissue depth. A single-tile image of the corpus
796 callosum at the midline, also at 0.31 μm x 0.31 μm in xy and z-interval of 1.5 μm ,
797 spanning the entire tissue depth was obtained for normalization. The same laser
798 settings were applied to both types of images and across all brains.

799

800 Tiled images of the cS1-S2 border region in mWGA-mCherry and GFP labeled brains
801 were also obtained with the 20X (NA 0.8) objective at 0.31 μm x 0.31 μm pixel size in xy
802 and z-interval of 1.5 μm , up to a depth of 12 μm . The same laser settings were applied
803 to all brains. A second, low-magnification, low intensity tiled image of the ipsilateral
804 cortex was obtained with the 10X objective. The same setting was applied to low-mag

805 low-intensity images of all brains. The fluorescence intensity of ipsilateral L2/3 GFP cell
806 bodies from these images was used as measure of IUE efficiency.
807 Zoomed images of L2/3 cell bodies were acquired for *Eph* receptor HCR and co-
808 expression analysis of L2/3 and S1 markers in electroporated neurons with a 40X oil-
809 immersion objective (NA 1.3) at 0.08 μm x 0.08 μm pixel size in xy and z-interval of 1
810 μm , spanning the entire tissue depth. Four coronal sections, separated from each other
811 by 125 μm and spanning the S1 barrel region were imaged for each brain. Care was
812 taken to ensure matching of anterior-posterior sections among different brains based on
813 DAPI-staining of landmarks. Three images were acquired of each section, at
814 approximately matched locations progression from the barrel field medial start to the
815 S1-S2 border. Laser power and gain settings were kept constant for all brains that were
816 quantified and compared as part of an experiment.

817
818 For analysis of cortical laminar organization, tiled images, spanning the Pia-to-WM axis
819 of the barrel cortex in height and ~ 600 μm (P7) or ~ 300 μm (E16.5) in width, were
820 obtained with a 20X (NA 0.8) objective at 0.31 μm x 0.31 μm pixel size in xy and z-
821 interval of 1.5 μm , spanning the entire tissue depth. Three to four coronal sections
822 separated from each other by 125 μm (P7) or 80 μm (E16.5) and spanning the S1 barrel
823 region were imaged for each brain. Care was taken to ensure matching of anterior-
824 posterior sections among different brains based on DAPI-staining of landmarks. Laser
825 power and gain settings were kept constant for all brains that were quantified and
826 compared as part of an experiment. Images used for display were cropped to a reduced
827 width.

828 Tiled images of entire brain sections were obtained with a 10X (NA 0.3) objective at
829 1.25 μm x 1.25 μm pixel size in xy and z-interval of 3 μm .

830 **QUANTIFICATION AND STATISTICAL ANALYSIS**

831 All image analyses were performed with FIJI/ImageJ⁹⁴ unless stated otherwise.

832 *Quantification of contralateral innervation and midline crossing*

833 To quantify raw axon innervation of the cS1/S2 border, the integrated density in a
834 manually drawn region of interest (ROI) was first obtained from high-intensity coronal

835 section images of electroporated brains. The horizontal extent of the ROI covered he
836 last two visible barrels in S1, and an equivalent distance in S2. Vertically, the ROI
837 covered all cortical layers up to the pia, but excluded sub-cortical white matter. DAPI
838 staining was used to determine the vertical and horizontal boundaries. At P8, the ROI
839 was drawn to cover the entire contralateral barrel field and a small portion of S2 close to
840 the S1-S2 border. The integrated fluorescence intensity in this ROI was treated as the
841 raw innervation.

842 To account for variability due to electroporation, we next obtained the integrated density
843 of an ROI spanning all labeled cell-bodies in ipsilateral L2/3 from low intensity images of
844 the same coronal section. The cS1/S2 integrated density measure was then divided by
845 the ipsilateral L2/3 cell body intensity to obtain the normalized cS1/S2 innervation value.

846 Using DAPI staining of anatomical landmarks, we ensured that matched coronal
847 sections were analyzed across all brains in a single experiment. Analysts were blinded
848 to genotype and/or IUE-based perturbation condition.

849 Quantification of midline crossing was also performed from maximum intensity
850 projection images of coronal sections. Integrated fluorescence intensity was calculated
851 in three manually drawn ROIs in the pre-crossing, midline, and post-crossing portions of
852 the corpus callosum and treated as raw values. These raw values were then then
853 divided by the ipsilateral L2/3 cell body intensity from low-intensity images for
854 normalization.

855 *Innervation profile analysis*

856 Innervation profiles along the Pia-to-WM axis of cS1-S2 and the medial-to-lateral axis of
857 the contralateral barrel field were first generated using the plot profile tool of Fiji/ImageJ
858 by analysts who were blind to the genotype. A vertical line spanning the Pi-to-WM axis
859 was extended into a rectangle of width 500 μm to cover the cS1-S2 border domain, and
860 the intensity profile along the vertical axis was generated. For intensity profiles along the
861 horizontal axis of the barrel field, a horizontal segmented line spanning the barrel field
862 and cS1-S2 was extended to form a polygon of width of 750 μm .

863 Raw intensity profiles were exported as .csv files and processed with a custom Python
864 script that normalized the total distance from 0 to 1 (WM to Pia in the vertical profiles,
865 and medial end to lateral end in the horizontal profiles). The script was then used to
866 calculate interval sums of intensity in 10 equally spaced intervals across the axis and to
867 plot the mean and standard deviation at each interval for each condition analyzed in the
868 experiment. Statistical comparisons were also performed using the script: first testing
869 the values at each interval for homogeneity of variance (Levene's test), and then
870 followed by an unpaired T-Test or a Mann-Whitney U-test, as appropriate. The p-values
871 obtained for each interval were adjusted for multiple comparisons with a Bonferroni
872 correction and adjusted p-values <0.05 were considered statistically significant.

873 *Quantification of EGFP:tdTomato intensity ratio in dual-labeled brains*

874 A custom-written Fiji/ImageJ macro was used to sum the total intensity, across all z-
875 planes, of individual channels of composite .czi z-stack images. This macro was
876 employed on composite images of cS1-S2 or the corpus callosum midline of brains from
877 dual labeling experiments to calculate the ratio of GFP to tdTomato channel intensity.
878 During imaging, DAPI-staining of anatomical landmarks was used to select matching
879 coronal sections across different brains for analysis.

880 *WGA cell counting*

881 DAPI staining was used to locate the cS1-S2 border region from tiled 20x z-stack
882 images of the contralateral cortex. L5 and L2/3 were next delineated in this region and
883 also based on DAPI staining. The total number of nuclei with perisomatic-WGA signal
884 were counted across individual z-planes in 300 μ m-wide rectangular regions of cS1-S2
885 L5 and cS1-S2 L2/3 and then summed to obtain the raw total contralateral WGA count.

886 Next, electroporation efficiency was calculated as the ipsilateral L2/3 GFP signal from
887 low-intensity 10x images of ipsilateral cortex of the same coronal section for which
888 contralateral WGA was quantified. Raw WGA count was then divided by ipsilateral L2/3
889 GFP intensity to obtain the normalized cC1-S2 WGA cell count. Analysts were blind to
890 genotype, and matching coronal sections were analyzed across all brains in the
891 experiment.

892 *HCR/ IHC analysis of electroporated L2/3 neurons*

893 *EphA* receptor mRNA HCR signal was quantified from high-magnification z-stack
894 images of electroporated L2/3 neurons by an analyst blind to genotype. 3-5 neurons
895 were chosen at random from each image for analysis. An ROI corresponding to the
896 neuron-cell body (marked by electroporated GFP) was delineated. This was done in the
897 z-plane where the cell-body area was largest for the chosen neuron *EphA6* HCR signal
898 intensity as well as the number of puncta within the ROI were recorded.

899 To quantify *Brn2*, *Cux1*, *Bhlhb5* and *CC3* co-expression, electroporated L2/3 neurons
900 and their appropriate z-plane were also chosen as described for HCR quantification.
901 They were then classified as positive (1) or negative (0) for the marker being assessed,
902 based on the IHC signal. Then, the total number of positive neurons was calculated for
903 each condition.

904 *HCR/ IHC analysis of cortical laminar markers*

905 Maximum projections of tiled images of P7 images of S1 cortex were first cropped to
906 width of 150 μm , while maintaining the entire height from Pia-to-WM. The total number
907 of *Ror β* ⁺, *Ctip2*⁺ and *Cux2*⁺*Ror β* ⁻ neurons were counted within this cropped region,
908 and the Pia-to-WM distance (cortical plate thickness) was also measured in the DAPI
909 channel. Counts and cortical thickness were obtained from images taken from four
910 coronal sections separated from each other by 125 μm and spanning the anterior-
911 posterior extent of the barrel cortex, and then averaged for each brain. Analysts who
912 performed the above operations were blinded to animal genotypes. This was then
913 followed by litter normalization, where the average value for all control (*Mef2c*^{FL/+}; *Nex-*
914 *Cre*) animals in a litter was normalized to 1.

915 Analysis of E16.5 S1 cortex laminar organization was performed similarly with a few
916 modifications. The cropped area used for counting was 100 μm wide, and *Brn2*⁺ and
917 *Ctip2*⁺ cell numbers and total DAPI nuclei were counted in this area. In addition, total
918 *RorB* HCR signal intensity within the cortical plate was measured. Images from three
919 coronal section, separated from each other by 80 μm , were quantified and averaged for

920 each brain. Values were then normalized to the control (*Mef2c^{FL/+}; Nex-Cre*) mean of
921 the litter.

922 *Statistical analysis*

923 All graphs were generated and statistical tests were performed using Prism version 10
924 (GraphPad) unless otherwise specified. Individual animals were considered as
925 biological replicates (n), and all experiments involve comparisons to littermate controls
926 except for the double-IUE experiments. The number of animals used (n), statistical
927 measures represented in graphs, statistical tests performed, and p-values are all
928 reported in the legends. The threshold for statistical significance was defined as p <
929 0.05.

930

931 **RESOURCE AVILABILITY**

932 ***Lead contact***

933 Further information and requests for resources and reagents should be directed to and
934 will be fulfilled by the lead contact, Alex L. Kolodkin (kolodkin@jhmi.edu).

935 ***Materials availability***

936 Plasmids generated in this study will be shared by the lead contact upon request

937 ***Data and code availability***

- 938 • Custom Python code and Fiji/ImageJ Macros will be made available publicly on
939 GitHub.
- 940 • Any additional information required to reanalyze the data reported in this paper is
941 available from the lead contact upon request.

942 **ACKNOWLEDGMENTS**

943 We are grateful to Dr. John Schwarz and Dr. Klaus-Armin Nave for kindly sharing
944 mouse strains, and Drs. Randal Hand, Soraia Barao, Ulrich Mueller, Xin Duan, Takuji
945 Iwasato, Constance Cepko, Takeshi Imai and Minmin Luo for their kind gifts of
946 plasmids. We thank Dr. Ulrich Mueller, Dr. Solange Brown, Dr. Soraia Barao, Yijun Xu,
947 Dr. Fengquan Zhou and all members of the Kolodkin laboratory for insightful discussion
948 and suggestions. We are especially grateful to Nicole Kropkowski and Dr. Victoria
949 Neckles for excellent technical assistance and laboratory management. This work was
950 supported by the Distinguished Graduate Student Fellowship from the Johns Hopkins
951 Kavli Neuroscience Discovery Institute to S.S, Johns Hopkins Neuroscience Scholars
952 Program Fellowship to L.G.C., and R03-TR004616 and Johns Hopkins School of
953 Medicine Institutional Funds to A.L.K.

954 **AUTHOR CONTRIBUTIONS**

955 Conceptualization, S.S., and A.L.K.; methodology, S.S., L.G-C., and A.L.K.; investigation,
956 S.S., L.G-C., N.D., and N.S.; writing—original draft, S.S., L.G-C., and A.L.K.; writing—
957 review & editing, S.S., L.G-C., J.Z., A.L.K.; funding acquisition, S.S., L.G-C., and A.L.K.;
958 resources, S.S, J.Z., and X.O.J.; supervision, A.L.K.

959 **DECLARATION OF INTERESTS**

960 The authors report no competing interests.

961 **SUPPLEMENTAL INFORMATION**

962 **Document S1. Figures S1–S7**

963

964 **FIGURE TITLES AND LEGENDS**

965 **Figure 1: *Mef2c* has dual roles in embryonic cortical laminar organization and**
966 **postnatal callosal axon projection targeting**

967 **(A and B):** *Mef2c* mRNA expression in sagittal sections at embryonic day 13.5 (E13.5)
968 (A) and E15.5 (B) is limited to post-mitotic neurons in the cortical plate. Insets in A' and
969 B': *Mef2c* expression in the cortical plate (CP) and underlying intermediate, sub-
970 ventricular and ventricular zones (IZ, SVZ+VZ). *Pax6* mRNA (magenta in A, A') marks
971 VZ progenitors and *Rorβ* (yellow in B, B') marks post-mitotic cortical layer 4 (L4)
972 neurons.

973 **(C-F):** Coronal sections through S1 of postnatal day (P) 7 *Nex-Cre; Mef2c^{FL/+}* Control
974 (C, D, E, F) and *Nex-Cre; Mef2c^{FL/FL}* mutant (C', D', E', F') littermates, immunostained
975 for laminar subtype markers. *Rorβ*⁺ L4 neurons were absent in the mutant cortex
976 (yellow asterix in D'), and *Ctip2*⁺ L5 neurons were reduced (F and F'), while *Cux2*⁺,
977 *Rorβ*⁻ L2/3 neurons were unaffected (C, E and C', E').

978 **(G-J)** Cortical thickness (G) and the number of Layer 5 (L5) *Ctip2*⁺ neurons (J) were
979 reduced, and Layer 4 (L4) *Rorβ*⁺ neurons were absent (H), while the Layer 2/3 (L2/3)
980 *Cux2*⁺, *Rorβ*⁻ neuron number was unchanged (I) in P7 *Nex-Cre; Mef2c^{FL/FL}* mice
981 compared to *Nex-Cre; Mef2c^{FL/+}* littermates. Graphs represent mean +/- standard
982 deviation (s.d), n=5 (C, D, F) mice, 3 litters or n=4 (E) mice, 2 litters, for each condition.
983 3-4 sections per animal were analyzed. Values were normalized to *Nex-Cre; Mef2c^{FL/+}*
984 littermate means. Mann-Whitney test, p=0.0079 (G) 0.0079 (H), 0.8857 (I), 0.0079 (J).

985 **(K and L):** *In situ* hybridization of (P0) (K) and P7 (L) sagittal sections, and insets (K', L')
986 of the S1 barrel field, reveal high *Mef2c* mRNA expression in L2/3 neurons. *Rorβ*
987 (magenta) marks L4 in sensory cortex.

988 **(M)** Fluorescence intensity profiles of *Mef2c* and *Rorβ* expression along the Pia-to-white
989 matter (WM) axis of S1 cortex at P0 (left) and P7 (right), showing high expression of
990 *Mef2c* in both L2/3 and L4 at P0, and a shift to L2/3-specific enrichment at P7.

991 **(N)** *In utero* electroporation (IUE) strategy in a single hemisphere with depicted
992 plasmids for conditional *Mef2c* knockout in post-mitotic S1-L2/3 neurons. Schematics
993 (right) illustrate expected labeling of electroporated cell bodies in S1 cortex and their
994 projections to their major targets: ipsilateral motor cortex (iM), ipsilateral secondary
995 somatosensory cortex (iS2) and the contralateral S1-S2 border (cS1-S2).

996 **(O and P)** Coronal sections of electroporated brains representative of *Mef2c*^{+/+} and
997 *Mef2c*^{FL/+} mice (Control: O, O') and homozygous *Mef2c*^{FL/FL} littermates (P, P') at P42.
998 *Mef2c*^{FL/FL} mice display reduced innervation (asterisk) of cS1-S2 (P'), compared to
999 Control (arrow, O').

1000 **(Q)** Quantification of cS1-S2 innervation reveals a reduction in targeting by *Mef2c*^{FL/FL}
1001 mutant S1-L2/3 neurons. Innervation was measured as integrated tRFP fluorescence in
1002 the boxed cS1-S2 region of high-exposure images, divided by electroporated ipsi-L2/3
1003 cell body intensity from low-exposure images for normalization (see Methods). Data are
1004 presented as median +/- intra-quartile range (IQR); whiskers represent range. n=8
1005 control and 5 *Mef2c*^{FL/FL} mice from 3 independent litters. Mann-Whitney U-test,
1006 p=0.0062.

1007 **(R)** Fluorescence intensity profiles of innervation along the Pia-to-WM axis of the cS1-
1008 S2 target domain at P42 show reduced innervation of *Mef2c*^{FL/FL} axons throughout the
1009 cortical wall. Data presented as mean +/- s.d of innervation intensity in bins that
1010 correspond to 1/10th of the normalized Pia-to-WM distance. n=8 control and 5 *Mef2c*^{FL/FL}
1011 mice from 3 independent litters. Mann Whitney U-test with Bonferroni correction for
1012 multiple comparisons, p=0.0155 at 0.75 and 0.85 Pia-to-WM; Unpaired T-test with
1013 Bonferroni correction, p=0.002 (0.95 Pia-to-WM), p=0.0336 (0.15 Pia-to-WM).

1014 ns, not significant; *, p<0.05; **, p<0.01; ***, p<0.005

1015 Scale bars: 500 μ m (A, B, K', L', P'), 200 μ m (A', B', F'), 1000 μ m (K, L), 2000 μ m (P),

1016 See also Figure S1 and Figure S2.

1017 **Figure 2: Dual labeling of Cre⁺ and Cre⁻ callosal projections in *Mef2c*-cKO brains,**
1018 **and L2/3 CPN specific *Mef2c* knockdown independently confirm cell autonomy of**
1019 ***Mef2c* function in CPN axon targeting**

1020 **(A)** Schematic of IUE-based dual-color labeling strategy to mark Cre⁺ neurons with
1021 EGFP and Cre⁻ neurons with tdTomato in the same brain.

1022 **(B)** Schematic representation of dual-labeling IUE outcome. All Cre⁺ neurons express
1023 EGFP, but a subset can co-express tdTomato due to incomplete recombination and/or
1024 perdurance of tdTomato.

1025 **(C-E)** A strong reduction of EGFP (Cre⁺) innervation was observed at cS1-S2 in the
1026 *Mef2c^{FL/FL}* brain (C', D') compared to tdTomato (Cre⁻) innervation in the same brain (C',
1027 E'). In the *Mef2c^{FL/+}* littermates, both EGFP and tdTomato innervation of cS1-S2 are
1028 comparable (C-E).

1029 **(F)** Quantification of innervation by Cre⁺ axons in cS1-S2 to Cre⁻ axons (ratio).
1030 *Mef2c^{FL/FL}* brains display a significantly lower ratio of Cre⁺: Cre⁻ axons when compared
1031 to *Mef2c^{FL/+}* control littermates. Data are presented as median +/- IQR; whiskers
1032 represent range. n=5 *Mef2c^{FL/+}* and 3 *Mef2c^{FL/FL}* mice from one litter. Mann-Whitney U-
1033 test, p=0.0357.

1034 **(G)** Schematic of IUE-based *Mef2c* knockdown using shRNA plasmids combined with
1035 an mCherry cell fill.

1036 **(H and I)** WT mice electroporated at E15.5 with shRNAs in S1. S1-L2/3 CPNs show
1037 reduced innervation of cS1-S2 upon *Mef2c* shRNA IUE (asterisk, I'), compared to
1038 littermates electroporated with Scrambled Control shRNA (H, H').

1039 **(J and K)** Quantification of cS1-S2 innervation, normalized to ipsilateral cell body
1040 intensity, reveals reduced cS1-S2 innervation by *shMef2c* neurons compared to
1041 *shScrambled* controls (J). IUE efficiency, measured by ipsilateral cell body intensity,
1042 was not significantly different between mutant and control. (Q). Data are presented as

1043 median +/- IQR; whiskers representing the range. n=5 *shScrambled* and 5 *shMef2c*
1044 mice from 2 independent litters. p=0.0079 (P) and 0.5476 (Q) Mann-Whitney U-test.

1045 ns, not significant; *, p<0.05; **, p<0.01.

1046 Scale bars: 200 μ m (C', E'), 2000 μ m (I), 500 μ m (I')

1047 See also Figure S3.

1048 **Figure 3: *Mef2c* specifically regulates target innervation, and not midline**
1049 **crossing, of callosal projection neurons**

1050 **(A and B)** Both *Mef2c*^{FL/+} (A, A') and *Mef2c*^{FL/FL} (B, B') E15.5-Cre-IUE brains exhibit
1051 normal midline crossing of S1-L2/3 CPNs at P4. However, post-crossing axon
1052 outgrowth is impaired for *Mef2c*^{FL/FL} axons (asterisks in B, B') compared to *Mef2c*^{FL/+}
1053 littermates (arrowhead, A).

1054 **(C and D)** *Mef2c*^{FL/+} control (C, C') or *Mef2c*^{FL/FL}(D, D') E15.5-Cre-IUE brains display no
1055 deficits in midline crossing or post-crossing white matter extension at P8.

1056 **(E)** IUE efficiency, measured as ipsilateral-cell body fluorescence, was not significantly
1057 different between the *Mef2c*^{FL/+} and *Mef2c*^{FL/FL} analyzed at P4. Signal intensity in the
1058 pre-crossing and midline regions of the corpus callosum, normalized to IUE-efficiency
1059 (see Methods), were not significantly different between *Mef2c*^{FL/+} and *Mef2c*^{FL/FL}; while
1060 there was a significant reduction in post-crossing corpus callosum signal intensity from
1061 *Mef2c*^{FL/FL} S1-L2/3 CPNs at P4 (right). Data are presented as median +/- IQR; whiskers
1062 represent range. n=5 *Mef2c*^{FL/+} and 5 *Mef2c*^{FL/FL} mice, 2 litters. Mann-Whitney U- test
1063 p=0.3095 (cell bodies), p=0.5476 (pre-cross), p=0.3095 (midline), p=0.0159 (post-
1064 cross).

1065 **(F)** IUE efficiency (left) and signal intensity in the pre-crossing, midline and post-
1066 crossing of the corpus callosum, normalized IUE-efficiency (right), were not significantly
1067 different between *Mef2c*^{FL/+} and *Mef2c*^{FL/FL} brains at P8, indicating recovery of the initial
1068 axon extension deficit seen at P4. Data are presented as median +/- IQR; whiskers
1069 represent the range. n=7 *Mef2c*^{FL/+} and 7 *Mef2c*^{FL/FL} mice, 2 litters. Mann-Whitney U-test:

1070 p=0.5350 (cell bodies), p=0.8357 (pre-cross), p=0.6282 (midline), p=0.8767 (post-
1071 cross).

1072 **(G and H)** Higher magnification images of the contralateral cortex at P8, showing that
1073 *Mef2c^{FL/+}* S1-L2/3 axons invaded the contralateral cortical plate (arrowhead in G), while
1074 *Mef2c^{FL/FL}* mutant S1-L2/3 axons were restricted to the white matter (asterisk in H).

1075 **(I)** Quantification of total innervation in the contralateral S1 cortical plate, normalized to
1076 ipsilateral L2/3 cell body intensity, showed a significant reduction in innervation by
1077 *Mef2c^{FL/FL}* S1-L2/3 neurons compared to *Mef2c^{FL/+}* controls. Data are presented as
1078 median +/- IQR; whiskers represent range. n=7 *Mef2c^{FL/+}* and 7 *Mef2c^{FL/FL}* mice, 2 litters.
1079 Mann-Whitney test: p=0.0006.

1080 **(J and K)** *Mef2c^{FL/+}* (J, J') or *Mef2c^{FL/FL}* (K, K') E15.5-Cre-IUE brains assessed at P14.
1081 *Mef2c^{FL/+}* S1-L2/3 CPN innervation is refined into columns targeting specific domains,
1082 like the cS1-S2 border (J'). Mutant S1-L2/3 axons remained confined to the contralateral
1083 white matter (K, K'), and failed to innervate cS1-S2 (asterisk, K').

1084 **(L)** Quantification of ipsilateral L2/3 cell body fluorescence (left) showed no significant
1085 difference between *Mef2c^{FL/+}* and *Mef2c^{FL/FL}* brains at P14(left). Quantification of cS1-
1086 S2, innervation, normalized to ipsilateral L2/3 cell body intensity, showed a significant
1087 reduction for *Mef2c^{FL/FL}* S1-L2/3 neurons compared to *Mef2c^{FL/+}* (right). Data are
1088 presented as median +/- IQR; whiskers represent range. n=9 *Mef2c^{FL/+}* and 8 *Mef2c^{FL/FL}*
1089 mice, 3 litters. Mann-Whitney test: p=0.8148 (cell bodies) and p=0.0010 (innervation).

1090 *, p<0.05; **, p<0.01; ****, p<0.001

1091 Scale bars: 2000 μ m (B, D, K), 500 μ m (B', D', H, K')

1092 **Figure 4: WGA anterograde tracing suggests *Mef2c* mutant S1-L2/3 CPNs fail to**
1093 **form synapses with contralateral cortical targets**

1094 **(A)** IUE experiment workflow to introduce plasmids expressing Cre, the Cre-dependent
1095 anterograde synaptic tracer mWGA-mCherry (mWmC), and a cell-label (GFP) in
1096 *Mef2c^{FL/FL}* embryos.

1097 **(B)** Schematic representation of IUE outcome. Electroporated neurons in ipsilateral S1
1098 are double-labeled with GFP and mCherry. At contralateral target regions, only neurons
1099 post-synaptic to the electroporated neurons will express perisomatic mCherry.

1100 **(C and D)** Images of cS1-S2 reveal a reduction in both GFP axonal innervation and
1101 mWmC post-synaptic partners of S1-L2/3 CPNs in the *Mef2c^{FL/FL}* brain (D, D')
1102 compared to those from Control littermates (C, C').

1103 **(E-H)** Multiple neurons show perisomatic mWmC as can be seen in high magnification
1104 insets of L2/3 (E) and L5 (F) in the Control brain, while almost none are detected in the
1105 *Mef2c^{FL/FL}* brain (G and H).

1106 **(I)** Fluorescence intensity profiles of axon innervation along the Pia-to-WM axis in cS1-
1107 S2 show reduced innervation of *Mef2c^{FL/FL}* axons throughout the cortical wall. Data
1108 presented as mean +/- s.d of innervation intensity in bins that correspond to 1/10th of the
1109 normalized Pia-to-WM distance. Mann Whitney U-test with Bonferroni correction for
1110 multiple comparisons: p=0.0233 at 0.85, 0.65 and 0.45 Pia-to-WM.

1111 **(J)** Quantification of mWmC⁺ cell-body number in cS1/S2 reveals *Mef2c^{FL/FL}* S1-L2/3
1112 neurons appear to synapse onto fewer targets compared to littermate Controls. Cell
1113 counts from L2/3 and L5 in the cS1-S2 were summed and divided by ipsilateral L2/3
1114 GFP intensity (from separate low-exposure images, see Methods) for normalization.
1115 Mann-Whitney U-test, p=0.0006.

1116 n=7 Control and 7 *Mef2c^{FL/FL}* animals from 2 litters; *, p<0.05; ****, p<0.001.

1117 Scale bars: 500 μ m (D'), 50 μ m (H').

1118 See also Figure S4.

1119 **Figure 5: *EphA6* expression is upregulated in *Mef2c*-mutant S1-L2/3 CPNs, and**
1120 ***EphA6* overexpression in WT S1-L2/3 CPNs leads to reduced contralateral target**
1121 **innervation**

1122 **(A)** Table details upregulated expression of *Eph* receptors in published bulk
1123 transcriptomic profiling of *Emx1-Cre; Mef2c^{FL/FL}*; vs *Cre-; Mef2c^{FL/FL}* Control P21
1124 cortex³⁴.

1125 **(B)** Experimental workflow to compare *EphA* receptor expression in Cre-electroporated
1126 S1-L2/3 CPNs in *Mef2c^{FL/+}* control and *Mef2c^{FL/FL}* brains. S1-L2/3 cell bodies were
1127 evaluated in 4 different sections from each brain, using 3 fields of view per section.

1128 **(C and D)** Cre-electroporated P8 S1-L2/3 CPN cell bodies (GFP⁺) in *Mef2c^{FL/+}* control
1129 (C-C'') and *Mef2c^{FL/FL}* (D-D'') mutant brains, hybridized with probes against *EphA6* and
1130 *EphA7*. *EphA6* expression is upregulated in mutant neurons (C' and D'), while *EphA7* is
1131 not differentially expressed (C'' and D'').

1132 **(E)** Quantification of fluorescence signal intensity (left) and puncta number (right) within
1133 GFP⁺ cell bodies both show a significant upregulation of *EphA6* expression in
1134 *Mef2c^{FL/FL}* S1-L2/3 neurons. Data are presented as mean +/- s.d for measures from
1135 individual neurons (left bars) and mean per neuron for individual mice (right bars) for
1136 each genotype. n=145 neurons from N=4 *Mef2c^{FL/+}* control and n=186 neurons from N=5
1137 *Mef2c^{FL/FL}* mice. Nested T-test: p=0.0276 (intensity), 0.0121 (puncta).

1138 **(F)** Domain organization of EphA receptors and Ephrin A (EfnA) ligands.

1139 **(G)** Experimental workflow to assess the effect of *EphA6* overexpression, using IUE, on
1140 S1-L2/3 neuron contralateral target innervation.

1141 **(H and I)** *EphA6* overexpression in WT S1-L2/3 neurons reduces innervation of
1142 contralateral targets (asterisk, I') compared to GFP-expressing Control neurons (arrow,
1143 H').

1144 **(J and K)** Quantification of cS1-S2 innervation, normalized to ipsilateral cell body
1145 intensity, shows significant reduction upon *EphA6* overexpression (J). Electroporation
1146 efficiency, measured as tRFP signal intensity of ipsilateral L2/3 cell bodies from low-
1147 exposure images, was not significantly different between the two conditions (K). Data
1148 are presented as median +/- IQR; whiskers represent range; n=9 GFP-control and 8

1149 EphA6-overexpression mice, 3 litters. Mann-Whitney U-test: $p=0.0025$ (J) and 0.5414
1150 (K).

1151 ns, not significant; *, $p<0.05$; ***, $p<0.005$.

1152 Scale bars: $50\ \mu\text{m}$ (D''), $2000\ \mu\text{m}$ (I), $500\ \mu\text{m}$ (I').

1153 See also Figure S5.

1154 **Figure 6: *EphA6* knockdown and dominant-negative expression in *Mef2c* mutant**
1155 **S1-L2/3 CPNs partially restore contralateral axon targeting**

1156 **(A)** Experimental workflow to assess the effect of expressing dominant-negative
1157 *EphA6 Δ ICD-GFP* on contralateral target innervation using IUE in *Mef2c^{FL/FL}* S1-L2/3
1158 neurons.

1159 **(B)** Schematic representation depicting the dominant-negative function of *EphA6 Δ ICD-*
1160 *GFP*.

1161 **(C and D)** *EphA6 Δ ICD-GFP* expression in *Mef2c^{FL/FL}* S1-L2/3 neurons (D) increases
1162 contralateral target innervation (arrow, D') as compared to GFP-expressing *Mef2c^{FL/FL}*
1163 neurons (C, asterisk in C').

1164 **(E and F)** Quantification showing increased cS1-S2 innervation, normalized to ipsilateral
1165 cell body intensity, upon *EphA6 Δ ICD* expression in *Mef2c^{FL/FL}* S1-L2/3 neurons
1166 compared to *Mef2c^{FL/FL}* neurons electroporated with GFP (E). Electroporation efficiency,
1167 measured as tRFP signal intensity of ipsilateral L2/3 cell bodies from low-exposure
1168 images, was significantly lower for *EphA6 Δ ICD* IUE compared to GFP IUE in *Mef2c^{FL/FL}*
1169 brains (F). Data are presented as median +/- IQR; whiskers represent range. $n=4$ GFP-
1170 control and 7 *EphA6 Δ ICD*-expressing brains, 3 independent litters. Mann-Whitney U-
1171 test: $p=0.0061$ for both (E) and (F).

1172 **(G)** Experimental workflow to assess the effect of *EphA6* knockdown, using IUE, on
1173 *Mef2c^{FL/FL}* S1-L2/3 neuron contralateral target innervation.

1174 **(H and I)** *EphA6* knockdown in *Mef2c^{FL/FL}* S1-L2/3 neurons (I) increased innervation of
1175 contralateral targets (arrow, I') compared to Scrambled shRNA-expressing *Mef2c^{FL/FL}*
1176 neurons (H, asterisk in H').

1177 **(J and K)** cS1-S2 innervation, normalized to ipsilateral cell body intensity, is significantly
1178 increased upon *EphA6* knockdown in *Mef2c^{FL/FL}* S1-L2/3 neurons compared to
1179 *Mef2c^{FL/FL}* + scrambled controls (J). Electroporation efficiency, measured as tRFP signal
1180 intensity of ipsilateral L2/3 cell bodies from low-exposure images, was not significantly
1181 different between the two groups (K). Data are presented as median +/- IQR; whiskers
1182 represent range. n=8 *shScram*-control and 6 *shEphA6* brains, 4 litters. Mann-Whitney
1183 U-test: p=0.0293 (J) and 0.4136 (K).

1184 ns, not significant; *, p<0.05; **, p<0.01.

1185 Scale bars: 2000 μ m (D, I), 500 μ m (D', I')

1186 See also Figure S6.

1187 **Figure 7: The repulsive ligand *EfnA5* is expressed in the contralateral target**
1188 **domain of S1-L2/3 CPNs, and innervation of *Mef2c* mutant neurons is partially**
1189 **restored upon *EfnA5* depletion at the target**

1190 **(A)** HCR *in situ* hybridization in coronal sections revealed that *EfnA5* was highly
1191 expressed in the developing barrel cortex, especially in deep layers, at P7. *Rorb* marks
1192 the barrel field (dashed outline).

1193 **(B)** *EfnA5* is expressed at very low levels in a different part of the developing cortex, the
1194 anterior motor region, where *Rorb* expression is also very low.

1195 **(C)** Model addressing the role of *EfnA5*-*EphA6* interaction in the reduction of
1196 contralateral barrel field innervation downstream of *Mef2c* LOF in S1-L2/3 CPNs. Under
1197 this model, we hypothesized that depletion of *EfnA5* from the contralateral barrel field
1198 should partially restore innervation by *Mef2c^{FL/FL}* S1-L2/3 CPNs from the ipsilateral side.

1199 **(D)** Double-IUE experimental workflow to (i) knockdown *EfnA5* in the contralateral barrel
1200 cortex, and (ii) label and knockout *Mef2c* in S1-L2/3 CPNs of the ipsilateral cortex, in the
1201 same brain.

1202 **(E and F)** High-magnification image of the contralateral barrel field from E12.5 contra-
1203 *shScrambled* (E) or contra-*shEfnA5* (F) double-IUE brains. GFP+ cell bodies, which
1204 express shRNA constructs, are broadly distributed throughout the deep layers (E'', F'').
1205 tRFP+ axons from *Mef2c^{FL/FL}* mutant ipsilateral S1-L2/3 neurons innervated a larger
1206 area in the *shEfnA5* cortex (F', F''') than in the *shScram* cortex (E', E''').

1207 **(G and H)** Coronal sections from double-IUE brains showing *Mef2c^{FL/FL}* S1-L2/3 CPNs
1208 labeled by tRFP, and expressing *shScrambled* (G, G') or *shEfnA5* (H, H') in the
1209 contralateral cortex. Mutant neurons displayed low cS1-S2 innervation in the control
1210 condition (asterisk, G'), but increased innervation upon *EfnA5* knockdown at the target
1211 (arrow, H').

1212 **(I and J)** cS1-S2 innervation by *Mef2c^{FL/FL}* S1-L2/3 neurons, normalized to ipsilateral
1213 cell body intensity, was significantly increased upon *EfnA5* knockdown in the
1214 contralateral cortex compared to *shScrambled* expression (I). Ipsilateral E15.5
1215 electroporation efficiency, measured as tRFP signal intensity of ipsilateral L2/3 cell
1216 bodies from low-exposure images, was not significantly different between the two
1217 groups (J). Data are presented as median +/- IQR; whiskers represent range. n=5
1218 contra-*shScrambled*-Control, 2 litters; and 8 contra-*shEfnA5*, 3 litters. Mann-Whitney U-
1219 test: p=0.0016 (I) and 0.5237 (J).

1220 ns, not significant; **, p<0.01.

1221 Scale bars: 500 μ m (A, B, F''', H'), 2000 μ m (H)

1222 See also Figure S7.

1223

1224 **REFERENCES**

- 1225 1. Aronoff, R., Matyas, F., Mateo, C., Ciron, C., Schneider, B., and Petersen, C.C.H.
1226 (2010). Long-range connectivity of mouse primary somatosensory barrel cortex.
1227 *Eur. J. Neurosci.* *31*, 2221–2233. [https://doi.org/10.1111/J.1460-](https://doi.org/10.1111/J.1460-9568.2010.07264.X)
1228 [9568.2010.07264.X](https://doi.org/10.1111/J.1460-9568.2010.07264.X).
- 1229 2. Liu, Y., Bech, P., Tamura, K., Délez, L.T., Crochet, S., and Petersen, C.C. (2024).
1230 Cell class-specific long-range axonal projections of neurons in mouse whisker-
1231 related somatosensory cortices. *Elife* *13*. <https://doi.org/10.7554/ELIFE.97602>.
- 1232 3. Fenlon, L.R., Suárez, R., and Richards, L.J. (2017). The anatomy, organisation
1233 and development of contralateral callosal projections of the mouse
1234 somatosensory cortex. <https://doi.org/10.1177/2398212817694888> *1*,
1235 [2398212817694888](https://doi.org/10.1177/2398212817694888). <https://doi.org/10.1177/2398212817694888>.
- 1236 4. Fame, R.M., MacDonald, J.L., and Macklis, J.D. (2011). Development,
1237 specification, and diversity of callosal projection neurons. *Trends Neurosci.* *34*,
1238 41–50. <https://doi.org/10.1016/J.TINS.2010.10.002>.
- 1239 5. de León Reyes, N.S., Bragg-Gonzalo, L., and Nieto, M. (2020). Development and
1240 plasticity of the corpus callosum. *Dev.* *147*. <https://doi.org/10.1242/DEV.189738>.
- 1241 6. Gavrish, M., Kustova, A., Celis Suescún, J.C., Bessa, P., Mitina, N., and
1242 Tarabykin, V. (2023). Molecular mechanisms of corpus callosum development: a
1243 four-step journey. *Front. Neuroanat.* *17*, 1276325.
1244 <https://doi.org/10.3389/FNANA.2023.1276325>.
- 1245 7. Alcamo, E.A., Chirivella, L., Dautzenberg, M., Dobрева, G., Fariñas, I.,
1246 Grosschedl, R., and McConnell, S.K. (2008). *Satb2* Regulates Callosal Projection
1247 Neuron Identity in the Developing Cerebral Cortex. *Neuron* *57*, 364–377.
1248 <https://doi.org/10.1016/J.NEURON.2007.12.012>.
- 1249 8. Britanova, O., de Juan Romero, C., Cheung, A., Kwan, K.Y., Schwark, M.,
1250 Gyorgy, A., Vogel, T., Akopov, S., Mitkovski, M., Agoston, D., et al. (2008). *Satb2*
1251 Is a Postmitotic Determinant for Upper-Layer Neuron Specification in the

- 1252 Neocortex. *Neuron* 57, 378–392. <https://doi.org/10.1016/j.neuron.2007.12.028>.
- 1253 9. Rodríguez-Tornos, F.M., Briz, C.G., Weiss, L.A., Sebastián-Serrano, A., Ares, S.,
1254 Navarrete, M., Frangeul, L., Galazo, M., Jabaudon, D., Esteban, J.A., et al.
1255 (2016). Cux1 Enables Interhemispheric Connections of Layer II/III Neurons by
1256 Regulating Kv1-Dependent Firing. *Neuron* 89, 494–506.
1257 <https://doi.org/10.1016/J.NEURON.2015.12.020>.
- 1258 10. Bormuth, I., Yan, K., Yonemasu, T., Gummert, M., Zhang, M., Wichert, S.,
1259 Grishina, O., Pieper, A., Zhang, W., Goebbels, S., et al. (2013). Neuronal Basic
1260 Helix–Loop–Helix Proteins Neurod2/6 Regulate Cortical Commissure Formation
1261 before Midline Interactions. *J. Neurosci.* 33, 641–651.
1262 <https://doi.org/10.1523/JNEUROSCI.0899-12.2013>.
- 1263 11. Yan, K., Bormuth, I., Bormuth, O., Tutukova, S., Renner, A., Bessa, P., Schaub,
1264 T., Rosário, M., and Tarabykin, V. (2023). TrkB-dependent EphrinA reverse
1265 signaling regulates callosal axon fasciculate growth downstream of Neurod2/6.
1266 *Cereb. Cortex* 33, 1752–1767. <https://doi.org/10.1093/CERCOR/BHAC170>.
- 1267 12. Bessa, P., Newman, A.G., Yan, K., Schaub, T., Dannenberg, R., Lajkó, D.,
1268 Eilenberger, J., Brunet, T., Textoris-Taube, K., Kemmler, E., et al. (2024).
1269 Semaphorin heterodimerization in cis regulates membrane targeting and
1270 neocortical wiring. *Nat. Commun.* 2024 151 15, 1–19.
1271 <https://doi.org/10.1038/s41467-024-51009-1>.
- 1272 13. Frazier, T.W., and Hardan, A.Y. (2009). A Meta-Analysis of the Corpus Callosum
1273 in Autism. *Biol. Psychiatry* 66, 935–941.
1274 <https://doi.org/10.1016/J.BIOPSYCH.2009.07.022>.
- 1275 14. Li, Q., Becker, B., Jiang, X., Zhao, Z., Zhang, Q., Yao, S., and Kendrick, K.M.
1276 (2019). Decreased interhemispheric functional connectivity rather than corpus
1277 callosum volume as a potential biomarker for autism spectrum disorder. *Cortex*
1278 119, 258–266. <https://doi.org/10.1016/J.CORTEX.2019.05.003>.
- 1279 15. Romaniello, R., Marelli, S., Giorda, R., Bedeschi, M.F., Bonaglia, M.C., Arrigoni,

- 1280 F., Triulzi, F., Bassi, M.T., and Borgatti, R. (2017). Clinical Characterization,
1281 Genetics, and Long-Term Follow-up of a Large Cohort of Patients with Agenesis
1282 of the Corpus Callosum. *J. Child Neurol.* 32, 60–71.
1283 <https://doi.org/10.1177/0883073816664668>.
- 1284 16. Cogger, R.W., and Serafetinides, E.A. (1990). Schizophrenia, corpus callosum,
1285 and interhemispheric communication: A review. *Psychiatry Res.* 34, 163–184.
1286 [https://doi.org/10.1016/0165-1781\(90\)90017-Y](https://doi.org/10.1016/0165-1781(90)90017-Y).
- 1287 17. Zhou, J., Wen, Y., She, L., Sui, Y.N., Liu, L., Richards, L.J., and Poo, M.M.
1288 (2013). Axon position within the corpus callosum determines contralateral cortical
1289 projection. *Proc. Natl. Acad. Sci. U. S. A.* 110, E2714–E2723.
1290 <https://doi.org/10.1073/PNAS.1310233110>.
- 1291 18. Pouloupoulos, A., Davis, P., Brandenburg, C., Itoh, Y., Galazo, M.J., Greig, L.C.,
1292 Romanowski, A.J., Budnik, B., and Macklis, J.D. (2024). Symmetry in levels of
1293 axon-axon homophilic adhesion establishes topography in the corpus callosum
1294 and development of connectivity between brain hemispheres. *bioRxiv*,
1295 2024.03.28.587108. <https://doi.org/10.1101/2024.03.28.587108>.
- 1296 19. Nishikimi, M., Oishi, K., Tabata, H., Torii, K., and Nakajima, K. (2011).
1297 Segregation and Pathfinding of Callosal Axons through EphA3 Signaling. *J.*
1298 *Neurosci.* 31, 16251–16260. <https://doi.org/10.1523/JNEUROSCI.3303-11.2011>.
- 1299 20. Potthoff, M.J., and Olson, E.N. (2007). MEF2: a central regulator of diverse
1300 developmental programs. *Development* 134, 4131–4140.
1301 <https://doi.org/10.1242/DEV.008367>.
- 1302 21. Li, H., Radford, J.C., Ragusa, M.J., Shea, K.L., McKercher, S.R., Zaremba, J.D.,
1303 Soussou, W., Nie, Z., Kang, Y.J., Nakanishi, N., et al. (2008). Transcription factor
1304 MEF2C influences neural stem/progenitor cell differentiation and maturation in
1305 vivo. *Proc. Natl. Acad. Sci. U. S. A.* 105, 9397–9402.
1306 <https://doi.org/10.1073/PNAS.0802876105>.
- 1307 22. Trudler, D., Ghatak, S., Bula, M., Parker, J., Talantova, M., Luevanos, M., Labra,

- 1308 S., Grabauskas, T., Noveral, S.M., Teranaka, M., et al. (2024). Dysregulation of
1309 miRNA expression and excitation in MEF2C autism patient hiPSC-neurons and
1310 cerebral organoids. *Mol. Psychiatry* 2024, 1–18. [https://doi.org/10.1038/s41380-](https://doi.org/10.1038/s41380-024-02761-9)
1311 [024-02761-9](https://doi.org/10.1038/s41380-024-02761-9).
- 1312 23. Latchney, S.E., Jiang, Y., Petrik, D.P., Eisch, A.J., and Hsieh, J. (2015). Inducible
1313 knockout of *Mef2a*, *-c*, and *-d* from nestin-expressing stem/progenitor cells and
1314 their progeny unexpectedly uncouples neurogenesis and dendritogenesis in vivo.
1315 *Neuron* 29, 5059–5071.
- 1316 24. Basu, S., Ro, E.J., Liu, Z., Kim, H., Bennett, A., Kang, S., and Suh, H. (2024). The
1317 *Mef2c* Gene Dose-Dependently Controls Hippocampal Neurogenesis and the
1318 Expression of Autism-Like Behaviors. *J. Neurosci.* 44.
1319 <https://doi.org/10.1523/JNEUROSCI.1058-23.2023>.
- 1320 25. Mayer, C., Hafemeister, C., Bandler, R.C., Machold, R., Batista Brito, R., Jaglin,
1321 X., Allaway, K., Butler, A., Fishell, G., and Satija, R. (2018). Developmental
1322 diversification of cortical inhibitory interneurons. *Nat.* 2018 5557697 555, 457–
1323 462. <https://doi.org/10.1038/nature25999>.
- 1324 26. Mao, Z., Bonni, A., Xia, F., Nadal-Vicens, M., and Greenberg, M.E. (1999).
1325 Neuronal activity-dependent cell survival mediated by transcription factor MEF2.
1326 *Science* (80-.). 286, 785–790. <https://doi.org/10.1126/SCIENCE.286.5440.785>.
- 1327 27. Li, Z., McKercher, S.R., Cui, J., Nie, Z., Soussou, W., Roberts, A.J., Sallmen, T.,
1328 Lipton, J.H., Talantova, M., Okamoto, S.I., et al. (2008). Myocyte Enhancer Factor
1329 2C as a Neurogenic and Antiapoptotic Transcription Factor in Murine Embryonic
1330 Stem Cells. *J. Neurosci.* 28, 6557–6568.
1331 <https://doi.org/10.1523/JNEUROSCI.0134-08.2008>.
- 1332 28. Akhtar, M.W., Kim, M.S., Adachi, M., Morris, M.J., Qi, X., Richardson, J.A.,
1333 Bassel-Duby, R., Olson, E.N., Kavalali, E.T., and Monteggia, L.M. (2012). In Vivo
1334 Analysis of MEF2 Transcription Factors in Synapse Regulation and Neuronal
1335 Survival. *PLoS One* 7, e34863.
1336 <https://doi.org/10.1371/JOURNAL.PONE.0034863>.

- 1337 29. Kamath, S.P., and Chen, A.I. (2019). Myocyte Enhancer Factor 2c Regulates
1338 Dendritic Complexity and Connectivity of Cerebellar Purkinje Cells. *Mol.*
1339 *Neurobiol.* *56*, 4102–4119. <https://doi.org/10.1007/S12035-018-1363-7>.
- 1340 30. Wu, R., Sun, Y., Zhou, Z., Dong, Z., Liu, Y., Liu, M., and Gao, H. (2024). MEF2C
1341 contributes to axonal branching by regulating Kif2c transcription. *Eur. J. Neurosci.*
1342 *59*, 3389–3402. <https://doi.org/10.1111/EJN.16344>.
- 1343 31. Flavell, S.W., Cowan, C.W., Kim, T.K., Greer, P.L., Lin, Y., Paradis, S., Griffith,
1344 E.C., Hu, L.S., Chen, C., and Greenberg, M.E. (2006). Activity-dependent
1345 regulation of MEF2 transcription factors suppresses excitatory synapse number.
1346 *Science (80-.)*. *311*, 1008–1012. <https://doi.org/10.1126/science.1122511>.
- 1347 32. Barbosa, A.C., Kim, M.S., Ertunc, M., Adachi, M., Nelson, E.D., McAnally, J.,
1348 Richardson, J.A., Kavalali, E.T., Monteggia, L.M., Bassel-Duby, R., et al. (2008).
1349 MEF2C, a transcription factor that facilitates learning and memory by negative
1350 regulation of synapse numbers and function. *Proc. Natl. Acad. Sci. U. S. A.* *105*,
1351 9391–9396. <https://doi.org/10.1073/PNAS.0802679105>.
- 1352 33. Tsai, N.-P., Wilkerson, J.R., Guo, W., Maksimova, M.A., Demartino, G.N., Cowan,
1353 C.W., and Huber, K.M. (2012). Multiple Autism-Linked Genes Mediate Synapse
1354 Elimination via Proteasomal Degradation of a Synaptic Scaffold PSD-95.
1355 <https://doi.org/10.1016/j.cell.2012.11.040>.
- 1356 34. Harrington, A.J., Raissi, A., Rajkovich, K., Berto, S., Kumar, J., Molinaro, G.,
1357 Raduazzo, J., Guo, Y., Loerwald, K., Konopka, G., et al. (2016). MEF2C regulates
1358 cortical inhibitory and excitatory synapses and behaviors relevant to
1359 neurodevelopmental disorders. *Elife* *5*. <https://doi.org/10.7554/ELIFE.20059>.
- 1360 35. Adachi, M., Lin, P.Y., Pranav, H., and Monteggia, L.M. (2016). Postnatal Loss of
1361 Mef2c Results in Dissociation of Effects on Synapse Number and Learning and
1362 Memory. *Biol. Psychiatry* *80*, 140–148.
1363 <https://doi.org/10.1016/J.BIOPSYCH.2015.09.018>.
- 1364 36. Rajkovich, K.E., Loerwald, K.W., Hale, C.F., Hess, C.T., Gibson, J.R., and Huber,

- 1365 K.M. (2017). Experience-Dependent and Differential Regulation of Local and
1366 Long-Range Excitatory Neocortical Circuits by Postsynaptic Mef2c. *Neuron* **93**,
1367 48–56. <https://doi.org/10.1016/J.NEURON.2016.11.022>.
- 1368 37. Putman, J.N., Watson, S.D., Zhang, Z., Khandelwal, N., Kulkarni, A., Gibson,
1369 J.R., and Huber, K.M. (2024). Pre- and Postsynaptic MEF2C Promotes
1370 Experience-Dependent, Input-Specific Development of Cortical Layer 4 to Layer
1371 2/3 Excitatory Synapses and Regulates Activity-Dependent Expression of
1372 Synaptic Cell Adhesion Molecules. *J. Neurosci.* **44**, e0098242024.
1373 <https://doi.org/10.1523/JNEUROSCI.0098-24.2024>.
- 1374 38. Assali, A., Harrington, A.J., and Cowan, C.W. (2019). Emerging roles for MEF2 in
1375 brain development and mental disorders. *Curr. Opin. Neurobiol.* **59**, 49–58.
1376 <https://doi.org/10.1016/J.CONB.2019.04.008>.
- 1377 39. Zhang, Z., and Zhao, Y. (2022). Progress on the roles of MEF2C in
1378 neuropsychiatric diseases. *Mol. Brain* **15**, 1–11. [https://doi.org/10.1186/S13041-](https://doi.org/10.1186/S13041-021-00892-6)
1379 [021-00892-6](https://doi.org/10.1186/S13041-021-00892-6).
- 1380 40. Leifer, D., Krainc, D., Yu, Y.T., McDermott, J., Breitbart, R.E., Heng, J., Neve,
1381 R.L., Kosofsky, B., Nadal-Ginard, B., and Lipton, S.A. (1993). MEF2C, a
1382 MADS/MEF2-family transcription factor expressed in a laminar distribution in
1383 cerebral cortex. *Proc. Natl. Acad. Sci. U. S. A.* **90**, 1546–1550.
1384 <https://doi.org/10.1073/PNAS.90.4.1546>.
- 1385 41. Leifer, D., Li, Y.L., and Wehr, K. (1997). Myocyte-specific enhancer binding factor
1386 2C expression in fetal mouse brain development. *J. Mol. Neurosci.* **8**, 131–143.
1387 <https://doi.org/10.1007/BF02736778>.
- 1388 42. Martin, J.F., Schwarz, J.J., and Olson, E.N. (1993). Myocyte enhancer factor
1389 (MEF) 2C: a tissue-restricted member of the MEF-2 family of transcription factors.
1390 *Proc. Natl. Acad. Sci.* **90**, 5282–5286. <https://doi.org/10.1073/PNAS.90.11.5282>.
- 1391 43. Flanagan, J.G., and Vanderhaeghen, P. (1998). The ephrins and Eph receptors in
1392 neural development. *Annu. Rev. Neurosci.* **21**, 309–345.

- 1393 <https://doi.org/10.1146/ANNUREV.NEURO.21.1.309>.
- 1394 44. Kania, A., and Klein, R. (2016). Mechanisms of ephrin–Eph signalling in
1395 development, physiology and disease. *Nat. Rev. Mol. Cell Biol.* 2016 174 17,
1396 240–256. <https://doi.org/10.1038/nrm.2015.16>.
- 1397 45. Triplett, J.W., and Feldheim, D.A. (2012). Eph and ephrin signaling in the
1398 formation of topographic maps. *Semin. Cell Dev. Biol.* 23, 7–15.
1399 <https://doi.org/10.1016/J.SEMCDB.2011.10.026>.
- 1400 46. Depaepe, V., Suarez-Gonzalez, N., Dufour, A., Passante, L., Gorski, J.A., Jones,
1401 K.R., Ledent, C., and Vanderhaeghen, P. (2005). Ephrin signalling controls brain
1402 size by regulating apoptosis of neural progenitors. *Nat.* 2005 4357046 435, 1244–
1403 1250. <https://doi.org/10.1038/nature03651>.
- 1404 47. Dimidschstein, J., Passante, L., Dufour, A., vandenAmeele, J., Tiberi, L.,
1405 Hrechdakian, T., Adams, R., Klein, R., Lie, D.C., Jossin, Y., et al. (2013). Ephrin-
1406 B1 controls the columnar distribution of cortical pyramidal neurons by restricting
1407 their tangential migration. *Neuron* 79, 1123–1135.
1408 <https://doi.org/10.1016/J.NEURON.2013.07.015>.
- 1409 48. He, C.H., Zhang, L., Song, N.N., Mei, W.Y., Chen, J.Y., Hu, L., Zhang, Q., Wang,
1410 Y.B., and Ding, Y.Q. (2022). *Satb2* Regulates EphA7 to Control Soma Spacing
1411 and Self-Avoidance of Cortical Pyramidal Neurons. *Cereb. Cortex* 32, 2321–2331.
1412 <https://doi.org/10.1093/CERCOR/BHAB321>.
- 1413 49. He, C.H., Song, N.N., Xie, P.X., Wang, Y.B., Chen, J.Y., Huang, Y., Hu, L., Li, Z.,
1414 Su, J.H., Zhang, X.Q., et al. (2023). Overexpression of EphB6 and EphrinB2
1415 controls soma spacing of cortical neurons in a mutual inhibitory way. *Cell Death*
1416 *Dis.* 2023 145 14, 1–11. <https://doi.org/10.1038/s41419-023-05825-w>.
- 1417 50. Mendes, S.W., Henkemeyer, M., and Liebl, D.J. (2006). Multiple Eph Receptors
1418 and B-Class Ephrins Regulate Midline Crossing of Corpus Callosum Fibers in the
1419 Developing Mouse Forebrain. *J. Neurosci.* 26, 882–892.
1420 <https://doi.org/10.1523/JNEUROSCI.3162-05.2006>.

- 1421 51. Bush, J.O., and Soriano, P. (2009). Ephrin-B1 regulates axon guidance by
1422 reverse signaling through a PDZ-dependent mechanism. *Genes Dev.* 23, 1586–
1423 1599. <https://doi.org/10.1101/GAD.1807209>.
- 1424 52. Mire, E., Hocine, M., Bazellères, E., Jungas, T., Davy, A., Chauvet, S., and
1425 Mann, F. (2018). Developmental Upregulation of Ephrin-B1 Silences
1426 Sema3C/Neuropilin-1 Signaling during Post-crossing Navigation of Corpus
1427 Callosum Axons. *Curr. Biol.* 28, 1768-1782.e4.
1428 <https://doi.org/10.1016/J.CUB.2018.04.026>.
- 1429 53. Zhou, J., Lin, Y., Huynh, T., Noguchi, H., Bush, J.O., and Pleasure, S.J. (2021).
1430 NMDA receptors control development of somatosensory callosal axonal
1431 projections. *Elife* 10.
- 1432 54. Vanderhaeghen, P., Lu, Q., Prakash, N., Frisé, J., Walsh, C.A., Frostig, R.D.,
1433 and Flanagan, J.G. (2000). A mapping label required for normal scale of body
1434 representation in the cortex. *Nat. Neurosci.* 2000 34 3, 358–365.
1435 <https://doi.org/10.1038/73929>.
- 1436 55. Prakash, N., Vanderhaeghen, P., Cohen-Cory, S., Frisé, J., Flanagan, J.G., and
1437 Frostig, R.D. (2000). Malformation of the Functional Organization of
1438 Somatosensory Cortex in Adult Ephrin-A5 Knock-Out Mice Revealed by In Vivo
1439 Functional Imaging. *J. Neurosci.* 20, 5841–5847.
1440 <https://doi.org/10.1523/JNEUROSCI.20-15-05841.2000>.
- 1441 56. Dufour, A., Seibt, J., Passante, L., Depaepe, V., Ciossek, T., Frisé, J., Kullander,
1442 K., Flanagan, J.G., Polleux, F., and Vanderhaeghen, P. (2003). Area specificity
1443 and topography of thalamocortical projections are controlled by ephrin/Eph genes.
1444 *Neuron* 39, 453–465. [https://doi.org/10.1016/S0896-6273\(03\)00440-9](https://doi.org/10.1016/S0896-6273(03)00440-9).
- 1445 57. Cang, J., Kaneko, M., Yamada, J., Woods, G., Stryker, M.P., and Feldheim, D.A.
1446 (2005). Ephrin-As Guide the Formation of Functional Maps in the Visual Cortex.
1447 *Neuron* 48, 577–589. <https://doi.org/10.1016/J.NEURON.2005.10.026>.
- 1448 58. Gao, P.P., Yue, Y., Zhang, J.H., Cerretti, D.P., Levitt, P., and Zhou, R. (1998).

- 1449 Regulation of thalamic neurite outgrowth by the Eph ligand ephrin-A5:
1450 Implications in the development of thalamocortical projections. *Proc. Natl. Acad.*
1451 *Sci. U. S. A.* *95*, 5329–5334. <https://doi.org/10.1073/PNAS.95.9.5329>.
- 1452 59. Liebl, D.J., Morris, C.J., Henkemeyer, M., and Parada, L.F. (2003). mRNA
1453 expression of ephrins and Eph receptor tyrosine kinases in the neonatal and adult
1454 mouse central nervous system. *J. Neurosci. Res.* *71*, 7–22.
1455 <https://doi.org/10.1002/JNR.10457>.
- 1456 60. Thompson, C.L., Ng, L., Menon, V., Martinez, S., Lee, C.-K., Glattfelder, K.,
1457 Sunkin, S.M., Henry, A., Lau, C., Dang, C., et al. (2014). A High-Resolution
1458 Spatiotemporal Atlas of Gene Expression of the Developing Mouse Brain. *Neuron*
1459 *83*, 309–323. <https://doi.org/10.1016/j.neuron.2014.05.033>.
- 1460 61. Goebbels, S., Bormuth, I., Bode, U., Hermanson, O., Schwab, M.H., and Nave,
1461 K.A. (2006). Genetic targeting of principal neurons in neocortex and hippocampus
1462 of NEX-Cre mice. *genesis* *44*, 611–621. <https://doi.org/10.1002/DVG.20256>.
- 1463 62. Vong, L.H., Ragusa, M.J., and Schwarz, J.J. (2005). Generation of conditional
1464 *Mef2*cre/loxP mice for temporal- and tissue-specific analyses. *genesis* *43*, 43–
1465 48. <https://doi.org/10.1002/GENE.20152>.
- 1466 63. Clark, E.A., Rutlin, M., Capano, L., Aviles, S., Saadon, J.R., Taneja, P., Zhang,
1467 Q., Bullis, J., Lauer, T., Myers, E., et al. (2020). Cortical ROR β is required for
1468 layer 4 transcriptional identity and barrel integrity. *Elife* *9*, 1–45.
1469 <https://doi.org/10.7554/ELIFE.52370>.
- 1470 64. Jabaudon, D., J. Shnider, S., J. Tischfield, D., J. Galazo, M., and MacKlis, J.D.
1471 (2012). ROR β Induces Barrel-like Neuronal Clusters in the Developing Neocortex.
1472 *Cereb. Cortex* *22*, 996–1006. <https://doi.org/10.1093/CERCOR/BHR182>.
- 1473 65. Nakagawa, Y., and O’Leary, D.D.M. (2003). Dynamic patterned expression of
1474 orphan nuclear receptor genes ROR α and ROR β in developing mouse
1475 forebrain. *Dev. Neurosci.* *25*, 234–244. <https://doi.org/10.1159/000072271>.
- 1476 66. Franco, S.J., Martinez-Garay, I., Gil-Sanz, C., Harkins-Perry, S.R., and Müller, U.

- 1477 (2011). Reelin Regulates Cadherin Function via Dab1/Rap1 to Control Neuronal
1478 Migration and Lamination in the Neocortex. *Neuron* 69, 482–497.
1479 <https://doi.org/10.1016/J.NEURON.2011.01.003>.
- 1480 67. Mizuno, H., Luo, W., Tarusawa, E., Saito, Y.M., Sato, T., Yoshimura, Y., Itoharu,
1481 S., and Iwasato, T. (2014). NMDAR-regulated dynamics of layer 4 neuronal
1482 dendrites during thalamocortical reorganization in neonates. *Neuron* 82, 365–379.
1483 <https://doi.org/10.1016/j.neuron.2014.02.026>.
- 1484 68. Luo, W., Mizuno, H., Iwata, R., Nakazawa, S., Yasuda, K., Itoharu, S., and
1485 Iwasato, T. (2016). Supernova: A Versatile Vector System for Single-Cell Labeling
1486 and Gene Function Studies in vivo. *Sci. Reports* 2016 61 6, 1–22.
1487 <https://doi.org/10.1038/srep35747>.
- 1488 69. Franco, S.J., Gil-Sanz, C., Martinez-Garay, I., Espinosa, A., Harkins-Perry, S.R.,
1489 Ramos, C., and Müller, U. (2012). Fate-restricted neural progenitors in the
1490 mammalian cerebral cortex. *Science* (80-.). 337, 746–749.
1491 <https://doi.org/10.1126/SCIENCE.1223616>.
- 1492 70. Tsai, N.Y., Wang, F., Toma, K., Yin, C., Takatoh, J., Pai, E.L., Wu, K., Matcham,
1493 A.C., Yin, L., Dang, E.J., et al. (2022). Trans-Seq maps a selective mammalian
1494 retinotectal synapse instructed by Nephronectin. *Nat. Neurosci.* 2022 255 25,
1495 659–674. <https://doi.org/10.1038/s41593-022-01068-8>.
- 1496 71. Mackarehtschian, K., Lau, C.K., Caras, I., and McConnell, S.K. (1999). Regional
1497 Differences in the Developing Cerebral Cortex Revealed by Ephrin-A5
1498 Expression. *Cereb. Cortex* 9, 601–610. <https://doi.org/10.1093/CERCOR/9.6.601>.
- 1499 72. Dorskind, J.M., Sudarsanam, S., Hand, R.A., Ziak, J., Amoah-Dankwah, M.,
1500 Guzman-Clavel, L., Soto-Vargas, J.L., and Kolodkin, A.L. (2023). Drebrin
1501 Regulates Collateral Axon Branching in Cortical Layer II/III Somatosensory
1502 Neurons. *J. Neurosci.* 43, 7745–7765. [https://doi.org/10.1523/JNEUROSCI.0553-](https://doi.org/10.1523/JNEUROSCI.0553-23.2023)
1503 [23.2023](https://doi.org/10.1523/JNEUROSCI.0553-23.2023).
- 1504 73. Ziak, J., Dorskind, J.M., Trigg, B., Sudarsanam, S., Jin, X.O., Hand, R.A., and

- 1505 Kolodkin, A.L. (2024). Microtubule-binding protein MAP1B regulates interstitial
1506 axon branching of cortical neurons via the tubulin tyrosination cycle. *EMBO J.*
1507 <https://doi.org/10.1038/S44318-024-00050-3>.
- 1508 74. Lin, R., Wang, R., Yuan, J., Feng, Q., Zhou, Y., Zeng, S., Ren, M., Jiang, S., Ni,
1509 H., Zhou, C., et al. (2018). Cell-type-specific and projection-specific brain-wide
1510 reconstruction of single neurons. *Nat. Methods* 2018 1512 15, 1033–1036.
1511 <https://doi.org/10.1038/s41592-018-0184-y>.
- 1512 75. Klein, R. (2012). Eph/ephrin signalling during development. *Development* 139,
1513 4105–4109. <https://doi.org/10.1242/DEV.074997>.
- 1514 76. Ueno, H., Colbert, H., Escobedo, J.A., and Williams, L.T. (1991). Inhibition of
1515 PDGF β Receptor Signal Transduction by Coexpression of a Truncated Receptor.
1516 *Science* (80-.). 252, 844–848. <https://doi.org/10.1126/SCIENCE.1851331>.
- 1517 77. Yue, Y., Chen, Z.Y., Gale, N.W., Blair-Flynn, J., Hu, T.J., Yue, X., Cooper, M.,
1518 Crockett, D.P., Yancopoulos, G.D., Tessarollo, L., et al. (2002). Mistargeting
1519 hippocampal axons by expression of a truncated Eph receptor. *Proc. Natl. Acad.*
1520 *Sci. U. S. A.* 99, 10777–10782. <https://doi.org/10.1073/PNAS.162354599>.
- 1521 78. Hand, R.A., Khalid, S., Tam, E., and Kolodkin, A.L. (2015). Axon Dynamics during
1522 Neocortical Laminar Innervation. *Cell Rep.* 12, 172–182.
1523 <https://doi.org/10.1016/j.celrep.2015.06.026>.
- 1524 79. Luo, L., and Flanagan, J.G. (2007). Development of Continuous and Discrete
1525 Neural Maps. *Neuron* 56, 284–300.
1526 <https://doi.org/10.1016/J.NEURON.2007.10.014>.
- 1527 80. Wang, C.L., Zhang, L., Zhou, Y., Zhou, J., Yang, X.J., Duan, S.M., Xiong, Z.Q.,
1528 and Ding, Y.Q. (2007). Activity-Dependent Development of Callosal Projections in
1529 the Somatosensory Cortex. 27. [https://doi.org/10.1523/JNEUROSCI.3380-](https://doi.org/10.1523/JNEUROSCI.3380-07.2007)
1530 [07.2007](https://doi.org/10.1523/JNEUROSCI.3380-07.2007).
- 1531 81. Mizuno, H., Hirano, T., and Tagawa, Y. (2007). Evidence for Activity-Dependent
1532 Cortical Wiring: Formation of Interhemispheric Connections in Neonatal Mouse

- 1533 Visual Cortex Requires Projection Neuron Activity. *J. Neurosci.* 27, 6760–6770.
1534 <https://doi.org/10.1523/JNEUROSCI.1215-07.2007>.
- 1535 82. Tezuka, Y., Hagihara, K.M., Ohki, K., Hirano, T., and Tagawa, Y. (2022).
1536 Developmental stage-specific spontaneous activity contributes to callosal axon
1537 projections. *Elife* 11. <https://doi.org/10.7554/ELIFE.72435>.
- 1538 83. Suárez, R., Fenlon, L.R., Marek, R., Avitan, L., Sah, P., Goodhill, G.J., and
1539 Richards, L.J. (2014). Balanced interhemispheric cortical activity is required for
1540 correct targeting of the corpus callosum. *Neuron* 82, 1289–1298.
1541 <https://doi.org/10.1016/J.NEURON.2014.04.040>.
- 1542 84. Zhou, J., Greenfield, A.L., Loudermilk, R., Bartley, C.M., Tran, B.T., Zhao, C.,
1543 Wang, H., Wilson, M.R., and Pleasure, S.J. (2023). Defective callosal termination
1544 underlies the long-term behavioral deficits in NMDA receptor antibody
1545 encephalitis mouse model. *bioRxiv*, 2022.09.29.510196.
1546 <https://doi.org/10.1101/2022.09.29.510196>.
- 1547 85. Chakrabarti, S., and Alloway, K.D. (2006). Differential origin of projections from SI
1548 barrel cortex to the whisker representations in SII and MI. *J. Comp. Neurol.* 498,
1549 624–636. <https://doi.org/10.1002/CNE.21052>.
- 1550 86. Klingler, E., Tomasello, U., Prados, J., Kebschull, J.M., Contestabile, A.,
1551 Galiñanes, G.L., Fièvre, S., Santinha, A., Platt, R., Huber, D., et al. (2021).
1552 Temporal controls over inter-areal cortical projection neuron fate diversity. *Nat.*
1553 2021 5997885 599, 453–457. <https://doi.org/10.1038/s41586-021-04048-3>.
- 1554 87. Janak, P.H., and Tye, K.M. (2015). From circuits to behaviour in the amygdala.
1555 *Nat.* 2015 5177534 517, 284–292. <https://doi.org/10.1038/nature14188>.
- 1556 88. Schumann, C.M., Bauman, M.D., and Amaral, D.G. (2011). Abnormal structure or
1557 function of the amygdala is a common component of neurodevelopmental
1558 disorders. *Neuropsychologia* 49, 745–759.
1559 <https://doi.org/10.1016/J.NEUROPSYCHOLOGIA.2010.09.028>.
- 1560 89. Greig, L.C., Woodworth, M.B., Galazo, M.J., Padmanabhan, H., and Macklis, J.D.

- 1561 (2013). Molecular logic of neocortical projection neuron specification,
1562 development and diversity. *Nat. Rev. Neurosci.* *14*, 755–769.
1563 <https://doi.org/10.1038/nrn3586>.
- 1564 90. Fellmann, C., Hoffmann, T., Sridhar, V., Hopfgartner, B., Muhar, M., Roth, M., Lai,
1565 D.Y., Barbosa, I.A.M., Kwon, J.S., Guan, Y., et al. (2013). An Optimized
1566 microRNA Backbone for Effective Single-Copy RNAi. *Cell Rep.* *5*, 1704–1713.
1567 <https://doi.org/10.1016/J.CELREP.2013.11.020>.
- 1568 91. Matsuda, T., and Cepko, C.L. (2007). Controlled expression of transgenes
1569 introduced by in vivo electroporation. *Proc. Natl. Acad. Sci. U. S. A.* *104*, 1027–
1570 1032. <https://doi.org/10.1073/PNAS.0610155104>.
- 1571 92. Fujimoto, S., Leiwe, M.N., Aihara, S., Sakaguchi, R., Muroyama, Y., Kobayakawa,
1572 R., Kobayakawa, K., Saito, T., and Imai, T. (2023). Activity-dependent local
1573 protection and lateral inhibition control synaptic competition in developing mitral
1574 cells in mice. *Dev. Cell* *58*, 1221-1236.e7.
1575 <https://doi.org/10.1016/J.DEVCEL.2023.05.004>.
- 1576 93. Peng, Y.R., James, R.E., Yan, W., Kay, J.N., Kolodkin, A.L., and Sanes, J.R.
1577 (2020). Binary Fate Choice between Closely Related Interneuronal Types Is
1578 Determined by a Fezf1-Dependent Postmitotic Transcriptional Switch. *Neuron*
1579 *105*, 464-474.e6. <https://doi.org/10.1016/J.NEURON.2019.11.002>.
- 1580 94. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch,
1581 T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an open-
1582 source platform for biological-image analysis. *Nat. Methods* *2012* *9*, 676–682.
1583 <https://doi.org/10.1038/nmeth.2019>.
- 1584

Figure 1




Figure 2




Figure 3




Figure 4




Figure 6




Figure 6




Figure 7

